US.LLY · Lilly (Eli)

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.4896478663461443,
        "turnoverUsdM": 2047.4321352445,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.LLY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 1060.1459,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 2,
        "rsi_score": 2.5,
        "macd_score": 1,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 5,
      "take_profit_price": 1171.4849,
      "target_multiplier": 1.6,
      "technical_strength": 1.45,
      "take_profit_percent": 5
    },
    "positionPoints": 1.8,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.979295732692289,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 44.9,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 41.9,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 3
  },
  "market": {
    "ma20": 1183.1245,
    "ma50": 1184.6546,
    "close": 1115.7,
    "prevClose": 1123,
    "avgVolume20": 2465266,
    "volumeRatio": 0.74,
    "changePercent": -0.65
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 3,
    "details": {
      "ret_5d": -0.037857908552223374,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 3,
      "vcp_bonus": 0,
      "vol_ratio": 0.7429971152386254,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.6351066468836497,
      "volat_points": 0,
      "day_range_pct": 0.016266084801742586,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 44.9,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 100,
        "contribution": 5
      },
      {
        "raw": 5.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 26,
        "contribution": 5.2
      },
      {
        "raw": 6.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 44,
        "contribution": 6.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 76,
        "contribution": 7.6
      },
      {
        "raw": 11.5,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 38.33,
        "contribution": 11.5
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 41.9,
    "details": [
      "基本面分析總分: 5/5分",
      "資金流分析總分: 5.2/20分",
      "市場環境分析總分: 6.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.6/10分",
      "技術信號分析總分: 11.5/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 5,
      "資金流": 5.2,
      "市場環境": 6.6,
      "情緒分析": 4,
      "技術信號": 11.5,
      "風險管理": 7.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.4,
          "marginPoints": 0.75,
          "turnoverUsdM": 2047.4321352445,
          "volumePoints": 0.5,
          "revenuePoints": 0.75,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 0.8,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.LLY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 2.8,
            "details": {
              "qqq": {
                "ma20": 715.6679992,
                "ma50": 710.4063990999997,
                "name": "QQQ",
                "close": 714.88,
                "points": 1.4
              },
              "spy": {
                "ma20": 766.87899445,
                "ma50": 758.61640102,
                "name": "SPY",
                "close": 764.28998,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.4896478663461443,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 2.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142079084,
                "url": "https://finnhub.io/api/news?id=e270340c9796ee31432952e4bf80bdf285c73c60ff6fe862d789ae64350a993e",
                "image": "https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) combines strong growth, high profitability, and a consolidating chart, offering a potential breakout setup for growth investors.",
                "category": "company",
                "datetime": 1789126848,
                "headline": "Eli Lilly (NYSE:LLY) Combines Strong Growth With a Quality Technical Setup"
              },
              {
                "id": 142064745,
                "url": "https://finnhub.io/api/news?id=ec7e31288ec30d3ed445c243aaa5470eb1ec4dfe7aa9137eda86ec50309ce44d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In the high-stakes world of big pharma, the slower-growing giant now commands the higher price, forcing investors to decide what that premium is truly buying.",
                "category": "company",
                "datetime": 1789067434,
                "headline": "Merck Stock Vs. LLY: Why Is The Slower Grower More Expensive?"
              },
              {
                "id": 142028628,
                "url": "https://finnhub.io/api/news?id=1197e6dcb84032bc3178511ebc59fde338fc46553b3e766a32b3e59929344ec1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]",
                "category": "company",
                "datetime": 1788981160,
                "headline": "Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks"
              },
              {
                "id": 141955069,
                "url": "https://finnhub.io/api/news?id=4dc2c173ec085ca2cac7bbf7a6e37cff6b8bf453dc400a3b4bda9476bca67c50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The latest trading day saw Eli Lilly (LLY) settling at $1, representing a -2.21% change from its previous close.",
                "category": "company",
                "datetime": 1788903908,
                "headline": "Here's Why Eli Lilly (LLY) Fell More Than Broader Market"
              },
              {
                "id": 141949973,
                "url": "https://finnhub.io/api/news?id=9395da7078966ee5ad77bd593e1d803d391072d348e14d3c8ec38c9585455e15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "According to the average brokerage recommendation (ABR), one should invest in Lilly (LLY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
                "category": "company",
                "datetime": 1788874203,
                "headline": "Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?"
              },
              {
                "id": 141437224,
                "url": "https://finnhub.io/api/news?id=38778bfaa72d5114c393b0f60959573175899d0ce0932c17d1256f7858796355",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535831,
                "headline": "Lilly (LLY) Down 2.7% Since Last Earnings Report: Can It Rebound?"
              },
              {
                "id": 141402768,
                "url": "https://finnhub.io/api/news?id=5e3b07fa04297498d247759e0ec46ddd6b8acd4569b066cb8b7a1f5e4c364fd1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE: LLY) agreed to acquire Merida Biosciences in a deal valued at up to US$2.88b to expand its immunology pipeline. The transaction brings Merida's platform for selectively degrading pathogenic autoantibodies while maintaining normal immune function into Lilly's portfolio. Merida's lead autoimmune and allergy candidate is in Phase 1 and is expected to support Lilly's move beyond its established focus on diabetes and obesity therapies. For readers looking to explore more...",
                "category": "company",
                "datetime": 1788455160,
                "headline": "What Does Eli Lilly (LLY) Gain From Its $2.88 Billion Immunology Deal?"
              },
              {
                "id": 141379511,
                "url": "https://finnhub.io/api/news?id=8780cdd6f1f1fad15e05dfd24f46c854de4ccc02b6ab97af39ced883123d9239",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's 10th deal of 2026 expands its immunology pipeline, underscoring an aggressive push to build growth drivers beyond its blockbuster cardiometabolic franchise.",
                "category": "company",
                "datetime": 1788361620,
                "headline": "Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?"
              }
            ],
            "raw_source": [
              {
                "id": 142090820,
                "url": "https://finnhub.io/api/news?id=a831718a3a30f9e9288df77d79cf0bd7be0a025f754b3ce18ad693b1179a1791",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Morgan Stanley sees Eli Lilly taking share before semaglutide's patents even become the bigger issue.",
                "category": "company",
                "datetime": 1789161044,
                "headline": "Morgan Stanley Downgrades Novo Nordisk to Sell on Lilly Competition"
              },
              {
                "id": 142089433,
                "url": "https://finnhub.io/api/news?id=4ae9498ecd56e299779ddffb0f6ac4ad216aa14954b49be19d26f04673465af6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AbbVie (ABBV) grew revenue 10.4% over the past twelve months and turned 33.9% of it into operating profit, second only to Eli Lilly among its peers on both counts. Its stock returned 24.9% over the same twelve months, fifth of the six. What the business delivered and what the market paid for it have come apart.",
                "category": "company",
                "datetime": 1789153872,
                "headline": "Is AbbVie Stock Actually Overpriced?"
              },
              {
                "id": 142088198,
                "url": "https://finnhub.io/api/news?id=3b75fcea1ca46c2af82b9f48bbc153be269bc756ea226fbb82b7172134a0d940",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The worst may be in the rearview mirror for the drugmaker.",
                "category": "company",
                "datetime": 1789147202,
                "headline": "Could This New Opportunity Be Worth Billions for Novo Nordisk?"
              },
              {
                "id": 142087054,
                "url": "https://finnhub.io/api/news?id=f51dea45b7a1313275e4193274729739aad97c9adc56b09b4facf9158c90c924",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Morgan Stanley Cuts Novo Nordisk to Underweight as Semaglutide Risks Cloud Outlook",
                "category": "company",
                "datetime": 1789140872,
                "headline": "Novo Nordisk Stock Plunges on Morgan Stanley Downgrade Warns of Semaglutide Patent Cliff"
              },
              {
                "id": 142087053,
                "url": "https://finnhub.io/api/news?id=d4c991c33a4ff0d4fa36573784487c15ef18d48f6d1e97d1fa2d0b1a10fb8107",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY's immunology portfolio is gaining ground, with steady revenue growth, pipeline expansion and acquisitions broadening its next wave.",
                "category": "company",
                "datetime": 1789140360,
                "headline": "Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s"
              },
              {
                "id": 142088208,
                "url": "https://finnhub.io/api/news?id=f6029aba4873dea296c598d1e5fe204dde17d8a51b84a48dc73af2405cc06827",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2214872699/image_2214872699.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "IHE trades at a P/E of 16.11x and is rated HOLD due to regulatory, patent, and concentration risks. Click for more details on the IHE fund.",
                "category": "company",
                "datetime": 1789134884,
                "headline": "IHE: Innovation Supports The Outlook, Valuation Limits Conviction"
              },
              {
                "id": 142088659,
                "url": "https://finnhub.io/api/news?id=bdc2f3449be06089f2a7a0fff4946e8fcf53edb531611c3d7f202790ddc443c0",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1789133712,
                "headline": "10 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 142088016,
                "url": "https://finnhub.io/api/news?id=9f1de9a72a876b2cb6e7aaa3e81ad72df2eeae2507ca22fd43cbc726b2a177eb",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/11/benzinga-deal-dispatch2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Read this week's top deal updates, including Bending Spoons' Miro deal, Chime's Stride Bank purchase, and the LIV Golf bankruptcy.",
                "category": "company",
                "datetime": 1789132210,
                "headline": "Deal Dispatch: Bending Spoons Acquires Miro For $1.35B, Kinetik Up For Sale, LIV Golf Bankruptcy"
              },
              {
                "id": 142084576,
                "url": "https://finnhub.io/api/news?id=914232955465c45cbd0487d9d9cc588e3c3b0c5998bd36878b479da8ec3ed614",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of AtaiBeckley Inc. AtaiBeckley is a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions, including BPL-003, its lead investigational program for treatment-resistant depression.",
                "category": "company",
                "datetime": 1789131720,
                "headline": "Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions"
              },
              {
                "id": 142087951,
                "url": "https://finnhub.io/api/news?id=b1963c52b2290da599197d9dd20463b110a492fcd9846a4bea269b40d100415b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/11/Eli-Lilly.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly is expanding into women's health, targeting endometriosis and pregnancy disorders by hiring experts and strategic investments.",
                "category": "company",
                "datetime": 1789127930,
                "headline": "Eli Lilly Utilizes Weight-Loss Drug Profits To Fund Women's Health Initiatives: Report"
              },
              {
                "id": 142079084,
                "url": "https://finnhub.io/api/news?id=e270340c9796ee31432952e4bf80bdf285c73c60ff6fe862d789ae64350a993e",
                "image": "https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) combines strong growth, high profitability, and a consolidating chart, offering a potential breakout setup for growth investors.",
                "category": "company",
                "datetime": 1789126848,
                "headline": "Eli Lilly (NYSE:LLY) Combines Strong Growth With a Quality Technical Setup"
              },
              {
                "id": 142071257,
                "url": "https://finnhub.io/api/news?id=3d7b15dadad954acdd86bca3089e30011162293312a5b7e71699e9adca681385",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "With products ranging from cardboard boxes to new drugs, these companies are all on track to double their earnings.",
                "category": "company",
                "datetime": 1789102800,
                "headline": "Growth Without AI: 8 Stock Picks"
              },
              {
                "id": 142075383,
                "url": "https://finnhub.io/api/news?id=f55cb0ffee0b789afadea6d663e4e72c30cb75467c30cdff4e7bb8367754f789",
                "image": "",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "",
                "category": "company",
                "datetime": 1789098300,
                "headline": "Second Quarter Earnings: A Rising AI Tide Lifts Many Sectors"
              },
              {
                "id": 142086503,
                "url": "https://finnhub.io/api/news?id=e628c29605c5f0847b5aef56a86ce8a16d5789c9f8ef65443d363904182bc5ce",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/11/Number-Of-Cigarettes-Isolated-Tobacco-Da.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "President Trump's Surgeon General nominee Dr. Nicole Saphier disclosed investments in Philip Morris and other companies, agreeing to divest if confirmed.",
                "category": "company",
                "datetime": 1789097046,
                "headline": "Trump's Surgeon General Pick Has Tobacco, Cola Stocks In Portfolio Even as Robert Kennedy Jr. Wages War On Sugary Drinks, Processed Food"
              },
              {
                "id": 142064745,
                "url": "https://finnhub.io/api/news?id=ec7e31288ec30d3ed445c243aaa5470eb1ec4dfe7aa9137eda86ec50309ce44d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In the high-stakes world of big pharma, the slower-growing giant now commands the higher price, forcing investors to decide what that premium is truly buying.",
                "category": "company",
                "datetime": 1789067434,
                "headline": "Merck Stock Vs. LLY: Why Is The Slower Grower More Expensive?"
              },
              {
                "id": 142064746,
                "url": "https://finnhub.io/api/news?id=1abe8e7dab24ae7989315403c7be9a89f24836f0d543d8d14ac5a49793d3b96e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "A healthcare titan is in a full sprint, but a recent stumble has investors asking if the best part of the race is already over.",
                "category": "company",
                "datetime": 1789063054,
                "headline": "JNJ Stock: Is the Rally Running Out of Steam?"
              },
              {
                "id": 142063180,
                "url": "https://finnhub.io/api/news?id=be3bacb593a16c63c5b7e86a008a5ce891e4258fdfe85d2e7db010e5d6ef3554",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Nvidia both just posted stunning quarters riding two of the biggest secular waves in markets today, but a $10,000 bet can only tilt one way. Which secular story holds the sharper edge heading into 2026?",
                "category": "company",
                "datetime": 1789061410,
                "headline": "Got $10,000? Eli Lilly vs. Nvidia: The Better Buy For 2026"
              },
              {
                "id": 142063283,
                "url": "https://finnhub.io/api/news?id=65f0ac67eae27fb2191dd56e7eb745fccf116fdc0af9a920181fbeed1f583b13",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly just crossed the trillion-dollar threshold on the back of a GLP-1 empire growing at nearly 50% annually, but a recent pullback and rising risks are forcing investors to decide whether this pharmaceutical giant still has meaningful upside left.",
                "category": "company",
                "datetime": 1789058116,
                "headline": "Eli Lilly Stock Has Become a Trillion-Dollar Giant. Is It Too Late to Buy?"
              },
              {
                "id": 142063284,
                "url": "https://finnhub.io/api/news?id=be50a481ebcc5df0107d02787d9814e4fad26b357f7714cbff406902f2e7efa6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "ABBV's Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.",
                "category": "company",
                "datetime": 1789055640,
                "headline": "AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next"
              },
              {
                "id": 142064240,
                "url": "https://finnhub.io/api/news?id=9f16182b6f60619c9f0346b9f16c061a9470814deb5845749f7759c1630268e7",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2256119617/image_2256119617.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novo Nordisk stays a Strong Buy after strong Q2 results and raised guidance. Click for more about the NVO stock.",
                "category": "company",
                "datetime": 1789053317,
                "headline": "Novo Nordisk: Valuation Reflects High Risk, But Solid Margin Of Safety"
              },
              {
                "id": 142061785,
                "url": "https://finnhub.io/api/news?id=319f28aeaea63b63ec1d3933aeb670aebb9c5465de023eaec04e187f46e57e89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AbbVie (ABBV) has returned 23.3% over the past year, ahead of the S&P 500's (SPY) 18.5%, and the business behind that return has changed shape. Humira, the drug whose decline management once explained, took one sentence on the July 2026 earnings call. What that sentence no longer contains is the part a holder should look at.",
                "category": "company",
                "datetime": 1789052702,
                "headline": "Why Has AbbVie Gone Quiet About Humira?"
              },
              {
                "id": 142061784,
                "url": "https://finnhub.io/api/news?id=b2af0f347c627fd20dd4fccaf4525cab85235efaf690a3948945cdf2eee5d02e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The obesity therapeutics market is becoming increasingly concentrated around an Eli Lilly–Novo Nordisk duopoly, with tirzepatide (ZEPBOUND) and semaglutide (WEGOVY) continuing to dominate the US branded treatment landscape. However, the competitive environment is evolving rapidly with the introduction of oral GLP-1 therapies. Novo Nordisk's oral WEGOVY surpassed 5 million cumulative US prescriptions within 30 weeks, while Eli Lilly's FOUNDAYO gained notable momentum among patients initiating ora",
                "category": "company",
                "datetime": 1789050660,
                "headline": "Obesity Market Set for Explosive 27% CAGR Growth by 2036, Fueled by 7 Promising Emerging Therapies | DelveInsight"
              },
              {
                "id": 142056972,
                "url": "https://finnhub.io/api/news?id=ac6bfec55c952757f1dd31a8a4d86dd2c7f957294e0f6d593b3bbf645dbdb478",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "This company aims to serve a market heading toward $100 billion.",
                "category": "company",
                "datetime": 1789036200,
                "headline": "Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There."
              },
              {
                "id": 142066014,
                "url": "https://finnhub.io/api/news?id=9831bb3499c3e752553a57056023c49232e73318d1bdba28085626c6d7a49b0c",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "HSBC  analyst Rajesh Kumar   maintains Eli Lilly (NYSE:LLY) with a Reduce and raises the price target from $850 to $940.",
                "category": "company",
                "datetime": 1789034250,
                "headline": "HSBC Maintains Reduce on Eli Lilly, Raises Price Target to $940"
              },
              {
                "id": 142048467,
                "url": "https://finnhub.io/api/news?id=df3f2d0447bcbea24c884db11f3ef15f60224c67c460adcd6a3931ab88c8edf7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly, Palo Alto Networks and Texas Instruments benefit from strong demand and strategic moves, while Stratus advances asset sales.",
                "category": "company",
                "datetime": 1789027560,
                "headline": "The Zacks Analyst Blog Highlights Eli Lilly, Palo Alto, Texas Instruments and Stratus Properties"
              },
              {
                "id": 142049134,
                "url": "https://finnhub.io/api/news?id=0862263c55b42d5a71af84f605119feccc3fd2c485769cf8a9acb69bfc40283c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/894549216/image_894549216.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Baron Opportunity Fund released its Q2 2026 portfolio updates and key investments. Read the full analysis for more details.",
                "category": "company",
                "datetime": 1789014000,
                "headline": "Baron Opportunity Fund Q2 2026 Adds And Trims"
              },
              {
                "id": 142029775,
                "url": "https://finnhub.io/api/news?id=d0ff98d5cde455307efefaec8b54174582b0f4755acdbee81ef2407f5701bc1a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly, Palo Alto Networks and Texas Instruments benefit from strong demand, strategic moves and growth prospects despite key risks.",
                "category": "company",
                "datetime": 1788986580,
                "headline": "Top Analyst Reports for Eli Lilly, Palo Alto Networks & Texas Instruments"
              },
              {
                "id": 142029776,
                "url": "https://finnhub.io/api/news?id=d0731908caf2bd1afebdf178ac483ad1e6acebd96431ddace79e6a6f8dcaac48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It was deliberately selling less medicine than people wanted to buy, and it kept saying so out loud.",
                "category": "company",
                "datetime": 1788986503,
                "headline": "What Eli Lilly Was Telling You While It Rationed Its Own Launches"
              },
              {
                "id": 142028628,
                "url": "https://finnhub.io/api/news?id=1197e6dcb84032bc3178511ebc59fde338fc46553b3e766a32b3e59929344ec1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]",
                "category": "company",
                "datetime": 1788981160,
                "headline": "Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks"
              },
              {
                "id": 142025909,
                "url": "https://finnhub.io/api/news?id=901d8e939e465dfa44ac5f6f9d5e7fe2e1722be31357eb7a2b50b6f17d1394c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Kura Oncology, Inc. (NASDAQ:KURA) on Wednesday announced $50 million financing tied to advancing its menin-inhibition strategy. Launches Caspian Therapeutics With $50 Million Financing Kura said it is launching Caspian Therapeutics alongside a $50 million financing led by BVF Partners, with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Co. (NYSE:LLY), Kura Oncology, members of Kura’s leadership team, and other investors. The stated goal is to advance the company’s work in meni",
                "category": "company",
                "datetime": 1788962256,
                "headline": "Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary"
              },
              {
                "id": 142026820,
                "url": "https://finnhub.io/api/news?id=8b0260feb9fcb3d808bd80def718c92efdb6b0332525b5c181772180baf2e750",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1404205960/image_1404205960.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Absci is rated SELL, as its valuation is highly concentrated on ABS-201 with limited partner revenue and an early-stage pipeline. Click for more on ABSI.",
                "category": "company",
                "datetime": 1788959272,
                "headline": "Absci's Billion-Dollar Hair Bet: Why The AI Story Doesn't Add Up"
              },
              {
                "id": 142024724,
                "url": "https://finnhub.io/api/news?id=dd8e631b9b07bac1d3fdab7717c62d52f885956485a88d4a82f29eb55e8e7602",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "PFE's non-COVID growth, oncology pipeline and cost cuts offer a path forward as COVID sales fall and patent losses loom.",
                "category": "company",
                "datetime": 1788955860,
                "headline": "Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?"
              },
              {
                "id": 142027356,
                "url": "https://finnhub.io/api/news?id=c7f3915aced5d132bdf96f5a81dc8f186bb3e092ea3cc7c893adcd1e5b4a055b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.",
                "category": "company",
                "datetime": 1788954840,
                "headline": "Kura spins diabetes work into a Lilly-backed biotech startup"
              },
              {
                "id": 142023813,
                "url": "https://finnhub.io/api/news?id=394cf59c9874759565d8f9b10a7f48c03daa8f3976225edb030cd728517b58d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech entrepreneurs – – Preclinical studies with KO-7246 demonstrate selective expansion of pancreatic β cells, increased endogenous insulin production, and improved glycemic control across multiple models of Type 1 and Type 2 diabetes – – Preclinical data supporting KO-7246 selected for oral pres",
                "category": "company",
                "datetime": 1788951600,
                "headline": "Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes"
              },
              {
                "id": 141998432,
                "url": "https://finnhub.io/api/news?id=07091e3b7dcb0e189aa6b2fa8f603144e67b69566b3d949a9d4faf83896c394a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Hint: It's a good idea to buy the stock today.",
                "category": "company",
                "datetime": 1788940200,
                "headline": "Prediction: This Is What a $5,000 Investment in Eli Lilly Will Be Worth in 2031"
              },
              {
                "id": 141955069,
                "url": "https://finnhub.io/api/news?id=4dc2c173ec085ca2cac7bbf7a6e37cff6b8bf453dc400a3b4bda9476bca67c50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The latest trading day saw Eli Lilly (LLY) settling at $1, representing a -2.21% change from its previous close.",
                "category": "company",
                "datetime": 1788903908,
                "headline": "Here's Why Eli Lilly (LLY) Fell More Than Broader Market"
              },
              {
                "id": 141955070,
                "url": "https://finnhub.io/api/news?id=5a7c5fc09850642d7a8caaee77916eedaa8d99a9804275b7f2e5c3820f97f82a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "US non-residential construction is approaching a reacceleration, driven by semiconductor and pharmac",
                "category": "company",
                "datetime": 1788902052,
                "headline": "Chip, Drug Makers to Drive Non-Residential Construction Rebound, UBS Says"
              },
              {
                "id": 141953735,
                "url": "https://finnhub.io/api/news?id=9c5e023692a02591c2928d2207009a175ee6a6707ea314b8c16db6a9bf6fc92d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Shifting emphasis from symptoms to biomarkers has bolstered sector confidence in emerging CNS therapies.",
                "category": "company",
                "datetime": 1788891208,
                "headline": "Why the CNS boom owes its success to breakthroughs in neurological pathologies"
              },
              {
                "id": 142026644,
                "url": "https://finnhub.io/api/news?id=c4785ecbd2042c377ead0a4cbb6d4c1a36d17f3471e988a68205021c5b0a253b",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 16.85% on an annualized basis producing an average annual return of 30.5%. Currently, Eli Lilly has a market capitalization of $1.00 trillion.",
                "category": "company",
                "datetime": 1788890440,
                "headline": "Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years"
              },
              {
                "id": 141952569,
                "url": "https://finnhub.io/api/news?id=bf55c65fe3939ab6df9422357c01cfad12866b74f6cce8d80aa6e5d8adc0da57",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop.",
                "category": "company",
                "datetime": 1788888917,
                "headline": "How Novartis' Double-Stacked Failures Reverberated Through Biopharma"
              },
              {
                "id": 141953736,
                "url": "https://finnhub.io/api/news?id=64ec7e58162b9cb86ffad30c64542a4ba313386083281b6953926d914a9c8d95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo announced successful results from a Phase 3 study of its injectable GLP1 drug Wegovy in obese children aged six to 12.",
                "category": "company",
                "datetime": 1788888900,
                "headline": "GLP1 Drugs Work for Kids, Says Novo Nordisk. They Could Be Another Huge Market."
              },
              {
                "id": 141952570,
                "url": "https://finnhub.io/api/news?id=5705e6aac332197632f6883717364f774adac3cf64f03b6da96a17c69f795736",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AbbVie (ABBV) trades at $256.46, roughly 96% of its 52-week high, after returning 24.1% over the past twelve months against 19.7% for the S&P 500. That price buys a business where about a third of guided 2026 revenue comes from one drug. The market reads that concentration as strength. It is worth reading it the other way too.",
                "category": "company",
                "datetime": 1788887331,
                "headline": "Is AbbVie Stock Too Reliant On Skyrizi?"
              },
              {
                "id": 141952567,
                "url": "https://finnhub.io/api/news?id=6c6b69135257c25c2784d50aea089d02ec194516dd752644de4bac87b74c9b2e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning.",
                "category": "company",
                "datetime": 1788887287,
                "headline": "Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%"
              },
              {
                "id": 141952508,
                "url": "https://finnhub.io/api/news?id=f53abdd25b71927826bd103d6cc2470c9328576117b490e2aa3d9d61da05b864",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe.",
                "category": "company",
                "datetime": 1788885300,
                "headline": "Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?"
              },
              {
                "id": 141953727,
                "url": "https://finnhub.io/api/news?id=07e7712374ded09ce7555b822278cc7f7309e17323d73b15523a179641d16736",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2292629985/image_2292629985.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Absci is upgraded to Buy after strong Phase 1 ABS-201 AGA data, solid PK/safety, and 2026–27 catalysts. Read the latest analysis on the stock here.",
                "category": "company",
                "datetime": 1788882698,
                "headline": "Absci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade)"
              },
              {
                "id": 141949985,
                "url": "https://finnhub.io/api/news?id=23e22eca29f124149162f38fb98cc7d4fd8a268c0cb690d6bdce0f160f07e68b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Merck (MRK) has returned about 85% over the past year and at about $150 trades roughly 4% below its 52-week high. A year ago, management spent earnings calls managing fallout from a steep drop in GARDASIL sales. That problem has left the lead. What management opens with instead is a much larger claim, and it settles years from now.",
                "category": "company",
                "datetime": 1788878194,
                "headline": "What Merck Stopped Saying About GARDASIL Should Change What You Watch"
              },
              {
                "id": 141949986,
                "url": "https://finnhub.io/api/news?id=a2ddda9620eb09f143e3bb978951298bddd4bf939901aecc3770087f4fb49d52",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop.",
                "category": "company",
                "datetime": 1788875819,
                "headline": "How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma"
              },
              {
                "id": 141949973,
                "url": "https://finnhub.io/api/news?id=9395da7078966ee5ad77bd593e1d803d391072d348e14d3c8ec38c9585455e15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "According to the average brokerage recommendation (ABR), one should invest in Lilly (LLY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
                "category": "company",
                "datetime": 1788874203,
                "headline": "Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?"
              },
              {
                "id": 141949987,
                "url": "https://finnhub.io/api/news?id=9ec2763621b10bdbd18024dfec19f1f8fd1385fb4d85e638a85d3a92475843d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.",
                "category": "company",
                "datetime": 1788873780,
                "headline": "Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study"
              },
              {
                "id": 141949988,
                "url": "https://finnhub.io/api/news?id=559b70828dd68378901bbdc4d09cdfbd4edcbaa457ee298110992feb7d1e8af0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Pelacarsen lowered Lp(a) levels in more than 8,000 patients but did not reduce the risk of heart attacks, strokes, or cardiovascular death",
                "category": "company",
                "datetime": 1788872181,
                "headline": "Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly"
              },
              {
                "id": 141949974,
                "url": "https://finnhub.io/api/news?id=b2ec4341f3666dff5619e2b1d8bf38bc580c8ddb9dd8a17f52bb9771272207d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new long-term driver beyond cardiometabolic therapies.",
                "category": "company",
                "datetime": 1788870420,
                "headline": "Lilly Builds Neuroscience into a New Long-Term Growth Driver"
              },
              {
                "id": 141949975,
                "url": "https://finnhub.io/api/news?id=01cd28316dcc302a685e7db7572680c66e03cface41b5168216c411e1740fcfb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "SOUTH SAN FRANCISCO & SAN DIEGO, September 08, 2026--Moonwalk Biosciences Announces $70 Million Series B Financing to Advance Adipose-Targeted RNAi Therapies for Obesity and Cardiometabolic Diseases",
                "category": "company",
                "datetime": 1788868800,
                "headline": "Moonwalk Biosciences Announces $70 Million Series B Financing to Advance Adipose-Targeted RNAi Therapies for Obesity and Cardiometabolic Diseases"
              },
              {
                "id": 141951906,
                "url": "https://finnhub.io/api/news?id=8516a4e5e27068b7c69780eccea33f98d398d6703fa4e598ec89e1e4baf85c7b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/08/Eli-Lilly-And-Company-Logo-On-Dark-Backg.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could benefit from renewed sector rotation.",
                "category": "company",
                "datetime": 1788866855,
                "headline": "Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back"
              },
              {
                "id": 141949976,
                "url": "https://finnhub.io/api/news?id=5bed09e97c6bea4ef633c2dd30e824625bb019205dbbcd9d7db231351b4910cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "4BIO Capital led upsized and oversubscribed round which includes strategic investment from AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund, reflecting depth of industry interest in this novel RNA therapeutics platformFinancing will support proof of concept in hepatocellular carcinoma and advancement of follow-on programs including colorectal cancer Cloverleaf’s tRNA therapeutic platform, has demonstrated significantly greater potency and selectivity for cancer cells over healthy ti",
                "category": "company",
                "datetime": 1788865500,
                "headline": "4BIO Capital leads oversubscribed $33 Million Seed Financing of Cloverleaf Bio, Advancing Novel RNA-Based Cancer Therapeutics"
              },
              {
                "id": 141949977,
                "url": "https://finnhub.io/api/news?id=b8bae068212e8a76ffc6ae004c463e0c3417467af5a2a75d3fac444382620828",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Cloverleaf Bio Raises $33 Million Seed Financing to Advance Novel RNA-Based Cancer Therapeutics Oversubscribed round led by 4BIO Capital includes strategic investment from AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund, reflecting depth of industry interest in this novel RNA therapeutics platformFinancing will support proof of concept in hepatocellular carcinoma and advancement of follow-on programs including colorectal cancer Cloverleaf’s tRNA therapeutic platform, has demonstrat",
                "category": "company",
                "datetime": 1788865200,
                "headline": "Cloverleaf Bio Raises $33 Million Seed Financing to Advance Novel RNA-Based Cancer Therapeutics"
              },
              {
                "id": 141949584,
                "url": "https://finnhub.io/api/news?id=5f4cfef0a7c2fddb118f970c476fd99960c387a98e0dde11fe681f82687d31dc",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/08/Los-Angeles--California---July-7-2025-El.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown, and market outlook analyzed.",
                "category": "company",
                "datetime": 1788862762,
                "headline": "Why Is Eli Lilly Stock Falling Tuesday?"
              },
              {
                "id": 141949322,
                "url": "https://finnhub.io/api/news?id=4327394c95660a20d019c67d42085de8642f275075d61e1337f760a5b7bc2062",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2285918278/image_2285918278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "NewAmsterdam Pharma (NAMS) has seen a near 40% stock pullback post-Merck’s Lipfendra approval, but retains multi-blockbuster potential with obicetrapib. Read the latest on the stock here.",
                "category": "company",
                "datetime": 1788862119,
                "headline": "NewAmsterdam Pharma: Potential Coupled With Uncertainty"
              },
              {
                "id": 141861687,
                "url": "https://finnhub.io/api/news?id=46ec764351227baa1b49ec0a975938ea8259f134a64b7f4b99c9bcadb772e81d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "STOCKHOLM, SE / ACCESS Newswire / September 8, 2026 / AB (\"AlzeCure\" or \"The Company\") (STO:ALZCUR)(FRA:AC6) , which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, today announced that the company will participate in Aktiespararna's Aktiedagen in Stockholm event on September 15. CEO Martin Jönsson will give a corporate presentation and provide an update on the company's recently announced out-licensing and collaboration agreements with Eli",
                "category": "company",
                "datetime": 1788855300,
                "headline": "AlzeCure Pharma to Present at Aktiedagen in Stockholm on September 15"
              },
              {
                "id": 141854767,
                "url": "https://finnhub.io/api/news?id=8de8a4d2fe443eb2e0cba51b0d86e33c7e2f86c98b21232d81b7038e6dd41f35",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Highlights rising patient prevalence, expanding use of cardio-renal therapies, pipeline innovation, and commercial opportunities across the seven major marketsDublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The \"Diabetic Nephropathy - Market Insight, Epidemiology, and Market Forecast - 2036\" has been added to ResearchAndMarkets.com's offering. The diabetic nephropathy and diabetes kidney disease (DKD) market reached approximately USD 8.80 billion in 2025 across the seven major markets (7MM): the Unit",
                "category": "company",
                "datetime": 1788854580,
                "headline": "Commercial Assessment of the Diabetic Nephropathy Market 2026-2036 Featuring Boehringer Ingelheim, Eli Lilly, Bayer, AstraZeneca, UCB Biopharma, Serodus, and Palatin"
              },
              {
                "id": 141772910,
                "url": "https://finnhub.io/api/news?id=f9083c7ce3229da948186592ac8f5dda25d21fa08d1b7f07247a327e006b263b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company’s (NYSE:LLY) Mounjaro has already become a major growth driver in diabetes treatment, and its latest FDA approval could strengthen that position by expanding what physicians can use the drug to accomplish. The FDA approved Mounjaro to reduce the risk of heart attack or stroke in adults with type 2 diabetes who […]",
                "category": "company",
                "datetime": 1788826466,
                "headline": "Could Mounjaro’s New Heart Benefit Unlock the Next Growth Phase for Lilly?"
              },
              {
                "id": 141805400,
                "url": "https://finnhub.io/api/news?id=d43beadbbb3aaf64615e53905264a9f77d720e5669b7801d3443c319ecf4a501",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly is worth 5.5x Novo Nordisk but earns nowhere near 5.5x more. Here's how the obesity pill war, a 13x vs. 32x valuation gap, and the dividend stack up, and which one I'd buy.",
                "category": "company",
                "datetime": 1788822002,
                "headline": "Eli Lilly vs. Novo Nordisk: One Has 39% Upside. I'm Picking the Other."
              },
              {
                "id": 141772911,
                "url": "https://finnhub.io/api/news?id=51f872fa53de8c1164b00771620cb1662be25e562349d25e9a5fbd40f210f43c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.",
                "category": "company",
                "datetime": 1788816900,
                "headline": "Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?"
              },
              {
                "id": 141771109,
                "url": "https://finnhub.io/api/news?id=29beab0809a7c2bc4164cb099588839029845495068a3c91385c65a59211c3d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Emerging therapies for ulcerative colitis treatment, such as Obefazimod (Abivax), Tulisokibart (Merck), Olamkicept (Ferring Pharmaceuticals), Afimkibart (Roche), Icotrokinra (Johnson & Johnson/Protagonist Therapeutics), Duvakitug (Teva Pharmaceuticals/Sanofi), Zotemtegrast (Eli Lilly), Zasocitinib (Takeda), XmAb942 (Xencor), and others, reflect a growing ulcerative colitis market, advancing novel mechanisms to address unmet needs in moderate-to-severe disease.New York, USA, Sept. 07, 2026 (GLOBE",
                "category": "company",
                "datetime": 1788800400,
                "headline": "Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight"
              },
              {
                "id": 141763843,
                "url": "https://finnhub.io/api/news?id=8e3a96e4ac86779de5d67800a375b6f80af9249e291b76853665ea38ecde2666",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.",
                "category": "company",
                "datetime": 1788793380,
                "headline": "Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?"
              },
              {
                "id": 141762863,
                "url": "https://finnhub.io/api/news?id=41ffd461059d01b83af5f6b005e0cd9ed487a6bbd0d0ecd81a797819bfe6cdb1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AZN's Etcamah wins accelerated FDA approval for certain advanced breast cancer patients, backed by a 56% risk reduction in progression or death.",
                "category": "company",
                "datetime": 1788784860,
                "headline": "AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah"
              },
              {
                "id": 141758397,
                "url": "https://finnhub.io/api/news?id=bb42b4fff5961915e0943d39451f7e871deed7c2986a302501fb247dccc82cdd",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2256862219/image_2256862219.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "4-Factor Dividend Growth Strategy targets high-quality, growth-oriented dividend stocks using a rules-based, four-metric screen. Learn more about the strategy here.",
                "category": "company",
                "datetime": 1788752600,
                "headline": "SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For September 2026"
              },
              {
                "id": 141593649,
                "url": "https://finnhub.io/api/news?id=5d9848968947aa31d10680f6defa1cfde3d0923ff4a8b499f6fb16adeca89801",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Investing.com -- Eli Lilly & Co is positioned for further growth in the booming obesity-drug market, with its Zepbound and Mounjaro treatments and a pipeline of next-generation therapies offering multiple avenues for upside, J.P. Morgan said in a research note.",
                "category": "company",
                "datetime": 1788734962,
                "headline": "Eli Lilly’s $100B incretin opportunity: Is more upside coming?"
              },
              {
                "id": 141762536,
                "url": "https://finnhub.io/api/news?id=755171ce4130cab475d6d9e4eb412f6569c568e60203dffab6ff579c86acade5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.",
                "category": "company",
                "datetime": 1788699000,
                "headline": "Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It"
              },
              {
                "id": 141593650,
                "url": "https://finnhub.io/api/news?id=1b6d133153dc2f29088c2b76da18608a1702e73335b7366b97b3a03c6488f4e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Is this big pharma stock still a buy for investors who aren't billionaires?",
                "category": "company",
                "datetime": 1788689460,
                "headline": "Here's Why Billionaires Stanley Druckenmiller and Ken Griffin Are Loading Up on Eli Lilly Stock"
              },
              {
                "id": 141546849,
                "url": "https://finnhub.io/api/news?id=ba5b5f19076fbfc31d0becce489b2ce3eb0ea9ed683a63f440debd292eee19d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's total return topped 367% over the past five years, largely thanks to enthusiasm for its GLP-1 offerings.",
                "category": "company",
                "datetime": 1788642480,
                "headline": "Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years"
              },
              {
                "id": 141539846,
                "url": "https://finnhub.io/api/news?id=eb3cfd6fe59e2a1a2f4ff417597cded259d241d2361cba00ca3cd67cd2e035d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Fundamentals, not a stock split, will determine whether the bull case for Eli Lilly continues.",
                "category": "company",
                "datetime": 1788634320,
                "headline": "Will Eli Lilly Split Its Stock? Here's What History Says Will Happen If It Does."
              },
              {
                "id": 141593651,
                "url": "https://finnhub.io/api/news?id=abd79ed984393837f1a616b04e48ecd336119888b355837cc8bf0f0db138fed0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.",
                "category": "company",
                "datetime": 1788615000,
                "headline": "Plastic surgery is booming with boomers. Here’s how to cash in on the antiaging craze."
              },
              {
                "id": 141593618,
                "url": "https://finnhub.io/api/news?id=c154a363f86768c4a1eb0f3e89657bd0c0c659ce2c8656bcf803e6ac740c27e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Stocks pulled back after a strong jobs report stoked rate-hike concerns. MarketBeat writers recap earnings-season themes, covering AI, cybersecurity, retail, energy, and dividend stocks.",
                "category": "company",
                "datetime": 1788609600,
                "headline": "MarketBeat Week in Review – 08/31 - 09/04"
              },
              {
                "id": 141509758,
                "url": "https://finnhub.io/api/news?id=81a0a262d8098c7ecccc6216fe28adcb2dd0d073ce0ee2611eab1c23e9613a97",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2289017666/image_2289017666.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "CRISPR Therapeutics' current $5.6B market cap and $1.78B net cash position offer acquisition appeal. Click to know why CRSP is rated a Buy.",
                "category": "company",
                "datetime": 1788588653,
                "headline": "CRISPR Therapeutics: CASGEVY Validates The Platform, Strengthening The Acquisition Case"
              },
              {
                "id": 141495006,
                "url": "https://finnhub.io/api/news?id=5f22b9493a7a9279946905d37b518c99a5c11ebc93d2bd25ebc92acdb074be14",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/171146347/image_171146347.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) stock looks attractive vs. overextended semiconductors, with strong Q2 growth and reasonable PEG. See here for more details.",
                "category": "company",
                "datetime": 1788571626,
                "headline": "Eli Lilly Stock Is Not Done Growing Yet, But It's Due For Compression (Rating Downgrade)"
              },
              {
                "id": 141481711,
                "url": "https://finnhub.io/api/news?id=a511f67f5ff6a8bcb766ee49bb72afe2cd94c5ef3991122eae3171f40821008e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) has launched Foundayo in the United Kingdom, making Britain the first European country where the company’s oral treatment for weight management and type 2 diabetes is available. The pill, known chemically as orforglipron, became available through private prescription after the UK medicines regulator authorised it on August 10. Its launch […]",
                "category": "company",
                "datetime": 1788569246,
                "headline": "Lilly Launches Foundayo in the UK as NICE Review Continues"
              },
              {
                "id": 141481712,
                "url": "https://finnhub.io/api/news?id=32dc6369c8c4692854a03ad7a10e5e7b739bfc7119a1fc5618cdb3c137eb677e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Testing for Alzheimer’s-related brain changes has traditionally depended on procedures that can be expensive, invasive, or difficult to access. Roche Holding AG and Eli Lilly and Company (NYSE:LLY) may now have a simpler way to help physicians evaluate certain patients. The FDA has cleared Elecsys pTau217, which is a blood test that helps identify whether […]",
                "category": "company",
                "datetime": 1788568671,
                "headline": "Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible?"
              },
              {
                "id": 141472595,
                "url": "https://finnhub.io/api/news?id=f9e7a0ac9416facd512c317e170c192de0c4b390576254368daff4b99ce9328f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The portfolio looks diversified. Cramer says look again",
                "category": "company",
                "datetime": 1788563220,
                "headline": "Jim Cramer flagged one stock quietly concentrating portfolios"
              },
              {
                "id": 141485601,
                "url": "https://finnhub.io/api/news?id=a14fa2d71c991d1424c650e89ccc0365f647e29aec84a754bdf9a4133b2e0743",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Explore this week’s dividend updates for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend and pay dates.",
                "category": "company",
                "datetime": 1788562641,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week September 6"
              },
              {
                "id": 141485634,
                "url": "https://finnhub.io/api/news?id=0d3fcb5f042d903617ab1078bdf535a591ed477284d1907ce582047fc9ca6b33",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1503371245/image_1503371245.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Bitcoin is trading on hike odds, falling from 81K to 76K on Warsh's hawkish tone and rebounding to 82.2K on Waller's dovish turn. Read more here.",
                "category": "company",
                "datetime": 1788562200,
                "headline": "Whale's Insight: Rate Hike? 6 Reasons The Fed Holds In September"
              },
              {
                "id": 141455023,
                "url": "https://finnhub.io/api/news?id=043d2048da751dd933ca2afda438cc2d3373e8aad99e40652d9e6f38d296f9a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk stock has fallen sharply over the past three years, yet valuation checks still lean toward the shares looking cheap rather than stretched. With fresh questions around obesity drug competition, patent risk and a changing leadership team, investors are weighing whether that discount is a warning sign or an opportunity. The share price has declined 51.9% over the past three years, which puts a clear spotlight on whether the current level already reflects the main concerns around...",
                "category": "company",
                "datetime": 1788548978,
                "headline": "Novo Nordisk (CPSE:NOVO B) Stock Looks Below Fair Value But Faces Earnings Doubts"
              },
              {
                "id": 141532987,
                "url": "https://finnhub.io/api/news?id=0b2e80aba0b3d7d5fe39a3ddb8053ff207155ae9867f3aa9a29972071b2862fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.",
                "category": "company",
                "datetime": 1788542100,
                "headline": "Revolution Medicines Got Its Breakthrough—What Moves It Next?"
              },
              {
                "id": 141444058,
                "url": "https://finnhub.io/api/news?id=905919b186b2cb70f624aa1750860bd8a239d54c5d4daa0db9581cc8254fae21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.",
                "category": "company",
                "datetime": 1788541047,
                "headline": "Was JNJ Stock Rally Actually Its Own?"
              },
              {
                "id": 141446624,
                "url": "https://finnhub.io/api/news?id=6ee251bee0e4adc49ca1434c8f2a4800aef47e288609cd223b6b582e4441cb6d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The maker of Mounjaro and Zepbound just signed its 13th deal of the year.",
                "category": "company",
                "datetime": 1788538620,
                "headline": "Lilly looks beyond obesity with $2.88B autoimmune buyout"
              },
              {
                "id": 141437224,
                "url": "https://finnhub.io/api/news?id=38778bfaa72d5114c393b0f60959573175899d0ce0932c17d1256f7858796355",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535831,
                "headline": "Lilly (LLY) Down 2.7% Since Last Earnings Report: Can It Rebound?"
              },
              {
                "id": 141465532,
                "url": "https://finnhub.io/api/news?id=8642a21a588ca8beed2d2338058c338b566779d9fc911fa7036e3c180f797820",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/04/benzinga-deal-dispatch2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Major M&A deals include Flex buys EPC Power for $4.4 Billion, KKR acquires A1 Garage Door, Starman Optical Buys GoPro.",
                "category": "company",
                "datetime": 1788533187,
                "headline": "Deal Dispatch: Nvidia Buys Hugging Face for $12.9 Billion, Barilla Acquires Goodles, Park Place Partners Bankruptcy"
              },
              {
                "id": 141431557,
                "url": "https://finnhub.io/api/news?id=313180c035e4932f2abc58e42e6e670c0e2e69ccec43a80dfb30eb8824b93639",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifies.",
                "category": "company",
                "datetime": 1788530700,
                "headline": "AMGN's MariTide: Can Convenience Drive its Obesity Market Share?"
              },
              {
                "id": 141446625,
                "url": "https://finnhub.io/api/news?id=c3f0ce25405e3a4a658c9e06cd609f8c5238342b85a42c14dd02819bf7143560",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Deals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this week. Meanwhile, Lilly has outpaced other pharmas in dealmaking this year.",
                "category": "company",
                "datetime": 1788522991,
                "headline": "This week in charts: China deals, stock flatlines and Lilly’s M&A spree"
              },
              {
                "id": 141425420,
                "url": "https://finnhub.io/api/news?id=cd208c2e553cff32ad09f454b0c0c8db9d130c40abe86b3fe821dc0abaaa8d6d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Superluminal Medicines will use the proceeds to advance its MC4R agonist candidate into Phase I trials by 2026.",
                "category": "company",
                "datetime": 1788520730,
                "headline": "Superluminal Medicines secures $60m to advance rare obesity therapy"
              },
              {
                "id": 141425422,
                "url": "https://finnhub.io/api/news?id=e9acc701f016eb70f80ae3f27a6985e589ef2b6c98dd82f09c9c97b81dfade70",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the month's most newsworthy and popular releases, here's a recap of some major stories from the last month that shouldn't be missed.",
                "category": "company",
                "datetime": 1788519720,
                "headline": "12 Top Press Releases from August"
              },
              {
                "id": 141405254,
                "url": "https://finnhub.io/api/news?id=b64183a96fb0637d3eda8aa3e12c3c99d2cc24cd7191118aef790d85a8f7a23e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Aspen's target is financially small today but creates an early map for GLP-1 expansion across Africa.",
                "category": "company",
                "datetime": 1788471320,
                "headline": "Lilly's African Mounjaro Push Starts at 1.25% of Quarterly Sales"
              },
              {
                "id": 141403789,
                "url": "https://finnhub.io/api/news?id=5a9b36d5b150db9606e301724999811af99ea2bd5f4726cd0be05631ada6b48a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "There is no end in sight for the company's incredible momentum.",
                "category": "company",
                "datetime": 1788459601,
                "headline": "Great News for Eli Lilly Stock Investors"
              },
              {
                "id": 141403790,
                "url": "https://finnhub.io/api/news?id=1548687fecf537e8e4484d6edea21ed97a99feddaf4fd5587f4cad353faadd83",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Drugmakers are getting a boost from strong earnings and M&A. But they’re also havens in a rocky market.",
                "category": "company",
                "datetime": 1788457140,
                "headline": "Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense"
              },
              {
                "id": 141401562,
                "url": "https://finnhub.io/api/news?id=1f94100c220d7a64393c01745fc80348758aa2c70eaf3e505da0a90106a9fa2b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.",
                "category": "company",
                "datetime": 1788455269,
                "headline": "Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?"
              },
              {
                "id": 141402768,
                "url": "https://finnhub.io/api/news?id=5e3b07fa04297498d247759e0ec46ddd6b8acd4569b066cb8b7a1f5e4c364fd1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE: LLY) agreed to acquire Merida Biosciences in a deal valued at up to US$2.88b to expand its immunology pipeline. The transaction brings Merida's platform for selectively degrading pathogenic autoantibodies while maintaining normal immune function into Lilly's portfolio. Merida's lead autoimmune and allergy candidate is in Phase 1 and is expected to support Lilly's move beyond its established focus on diabetes and obesity therapies. For readers looking to explore more...",
                "category": "company",
                "datetime": 1788455160,
                "headline": "What Does Eli Lilly (LLY) Gain From Its $2.88 Billion Immunology Deal?"
              },
              {
                "id": 141401563,
                "url": "https://finnhub.io/api/news?id=50bde06ec4383c3e8fc1744e10def00da142de1f05932785daae894c39691680",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.",
                "category": "company",
                "datetime": 1788454466,
                "headline": "ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?"
              },
              {
                "id": 141400340,
                "url": "https://finnhub.io/api/news?id=d605837c09a466bf298019b4b1f79af8743705ece69897637d710b520f1b2b7e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Johnson & Johnson (JNJ) has had a good year. The stock is up 56.5% over the past twelve months against 19.1% for the S&P 500, and at $271.19 sits at about 99% of its 52-week high. The business is still growing. The risk is that the current stock price discounts an acceleration well ahead of management's near-term guidance.",
                "category": "company",
                "datetime": 1788449092,
                "headline": "Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?"
              },
              {
                "id": 141400341,
                "url": "https://finnhub.io/api/news?id=ad022e5bc8dde3e4d944411bba52005d8a98c7c6847a875884ffee4bfc31fea2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "PFE's pipeline is taking center stage as berobenatide and next-generation oncology drugs aim to drive growth from 2028 and beyond.",
                "category": "company",
                "datetime": 1788448140,
                "headline": "Pfizer's Pipeline Strategy Centers on Obesity and Oncology"
              },
              {
                "id": 141397311,
                "url": "https://finnhub.io/api/news?id=92b933b6df4d47cc063de84685b5e1996f58ee386b3cb9050f57d32811573e8c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Superluminal Medicines, a biotechnology company integrating AI/ML, protein dynamics and structural biology to rapidly unlock some of the most challenging G protein-coupled receptor (GPCR) targets, today announced the closing of an oversubscribed $60 million Series B financing. Proceeds will support advancing Superluminal's lead program for rare genetic forms of obesity and hypothalamic obesity, expected to begin by the end of 2026; advancing additional pipeline programs; and further expanding th",
                "category": "company",
                "datetime": 1788429600,
                "headline": "Superluminal Medicines Announces Oversubscribed $60 Million Series B Financing to Advance Lead Program in Rare Genetic Forms of Obesity into the Clinic"
              },
              {
                "id": 141396032,
                "url": "https://finnhub.io/api/news?id=a32f7735f3ea5b3d74103306bc5706c087f62c149599806c91620a22613dca82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Tokyo, Japan and Cambridge, UK, 3 September 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals Limited (“Centessa”), a wholly-owned subsidiary of Eli Lilly and Company (“Lilly”), has achieved a late-stage development milestone associated with its selective orexin receptor 2 (OX2R) agonist portfolio. This milestone triggers a payment of US$8.6 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment",
                "category": "company",
                "datetime": 1788417240,
                "headline": "Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress"
              },
              {
                "id": 141383135,
                "url": "https://finnhub.io/api/news?id=26f0698fa865430f134d6aa1291f98e664919bd72ce27b415e48e336012c9fd8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "President Donald Trump has secured new drug pricing agreements with nine pharmaceutical companies, with an aim to align the prices of drugs in the U.S. with international prices. The companies include Alcon Inc., Astellas Pharma, BeOne Medicines Ltd., BridgeBio, CSL,...",
                "category": "company",
                "datetime": 1788386407,
                "headline": "Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President"
              },
              {
                "id": 141381110,
                "url": "https://finnhub.io/api/news?id=3c3218bcaea97bcb318017155db1870e5c2d299f97bce09448cd4f5b0c6401c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The drug giant added to its immunotherapy portfolio.",
                "category": "company",
                "datetime": 1788382980,
                "headline": "Eli Lilly Just Announced a Major Acquisition. Here's What It Means."
              },
              {
                "id": 141379512,
                "url": "https://finnhub.io/api/news?id=9be7c04f830c89c2f8ee15f925fd3040018c7948d526e1f36ab373173ca05fdc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "HIMS raised its 2026 revenue outlook after Q2 sales jumped 38.2%, but margin contraction and an $86.3 million net loss highlighted growth costs.",
                "category": "company",
                "datetime": 1788377400,
                "headline": "HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss"
              },
              {
                "id": 141379513,
                "url": "https://finnhub.io/api/news?id=b83ed80afcb80cbd4652b6ca44f619ec245ce1285bf164a2fe2279ae839bfc54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Before the eighty-five percent surge, the company's pipeline story was getting louder just as its revenue trajectory was getting quieter.",
                "category": "company",
                "datetime": 1788373011,
                "headline": "How Did Merck Stock Beat The Market With Slowing Sales?"
              },
              {
                "id": 141379510,
                "url": "https://finnhub.io/api/news?id=1d5c9b35d39928d5a99d5e0aeec97f11488bb44326b3daa14fb17eea770cad68",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly just delivered one of the biggest quarters in Big Pharma history, yet the stock sits well below its 52-week high. A closer look at the pipeline and valuation reveals why the real opportunity may still be ahead.",
                "category": "company",
                "datetime": 1788370234,
                "headline": "Lilly’s Record Stock Price Is Hiding an Even Bigger Opportunity"
              },
              {
                "id": 141379514,
                "url": "https://finnhub.io/api/news?id=be26bbec50ca5a5b43eebb50858927fd3ecc60fec2a00862e209b8f346cbf49c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AstraZeneca's pipeline setbacks weigh on the stock, but blockbuster drugs, oncology growth and a strong launch pipeline offer reasons to stay invested.",
                "category": "company",
                "datetime": 1788361800,
                "headline": "AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks"
              },
              {
                "id": 141379511,
                "url": "https://finnhub.io/api/news?id=8780cdd6f1f1fad15e05dfd24f46c854de4ccc02b6ab97af39ced883123d9239",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's 10th deal of 2026 expands its immunology pipeline, underscoring an aggressive push to build growth drivers beyond its blockbuster cardiometabolic franchise.",
                "category": "company",
                "datetime": 1788361620,
                "headline": "Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?"
              },
              {
                "id": 141400339,
                "url": "https://finnhub.io/api/news?id=5f556c6a4d5ebefa62a309a262ca7245aa935da98a6cdfb33a9b62e16226151d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly's $2.875 billion Merida Biosciences deal expands its immunology pipeline, as strong GLP-1 growth continues while LLY shares trail the broader health care sector.",
                "category": "company",
                "datetime": 1788361200,
                "headline": "Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity"
              },
              {
                "id": 141376364,
                "url": "https://finnhub.io/api/news?id=838401a6e8e45d155e1feb8b1fdbff809a833b086a596070a1e9d3c6e8f33d6d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Karsten Eastman, CEO of Sethera Therapeutics, discusses developments in peptides from cutting-edge innovation to mass consumption.",
                "category": "company",
                "datetime": 1788354321,
                "headline": "Peptide innovator says the drug class is due for a rethink"
              },
              {
                "id": 141377683,
                "url": "https://finnhub.io/api/news?id=85ffe7846c796c19e99f3579fdfa35bdf1d8d1f2e3274c00814bb35b7aec473c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260312486/image_2260312486.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "The September 2026 Top 25 High-Growth Dividend Stocks list targets quality companies trading below intrinsic value with strong long-term return potential.",
                "category": "company",
                "datetime": 1788344147,
                "headline": "Top 25 High-Growth Dividend Stocks For September 2026"
              },
              {
                "id": 141378100,
                "url": "https://finnhub.io/api/news?id=191546a2e63ca0d90b98f703a62b10eebbad57806ce95d35804e82b65f75f0ef",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/02/Weight-loss-lawsuits.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "FDA warns of risks from unapproved compounded GLP-1 drugs including semaglutide and tirzepatide amid rising adverse event reports.",
                "category": "company",
                "datetime": 1788334823,
                "headline": "Fraudulent Weight Loss Drugs: FDA Warns Against Mislabeled GLP-1 Medications"
              },
              {
                "id": 141372509,
                "url": "https://finnhub.io/api/news?id=fe39252280e118ff2fa8880a440babc7b5b782509ec2959aebf8fd673a741e95",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "GMO’s 13F portfolio jumps to ~$44B. See top holdings, key buys/sells, and rebalancing across tech, healthcare & financials—read the update now.",
                "category": "company",
                "datetime": 1788296759,
                "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q2 2026 Update"
              },
              {
                "id": 141373018,
                "url": "https://finnhub.io/api/news?id=24c656c93f1c91e679fe151586ad9f7297a16a7c9952b4ba8f13a3f2a3b2acf8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The high-flying healthcare leader looks unstoppable right now.",
                "category": "company",
                "datetime": 1788294006,
                "headline": "This New Zepbound Study Could Be Great News for Eli Lilly Investors"
              },
              {
                "id": 141369811,
                "url": "https://finnhub.io/api/news?id=466c6ed0945e1281e7add0d053043b0d67926783339804f46b60c9e56c8f4553",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Germany becomes the first EU market for oral Wegovy, testing Novo's early lead as Eli Lilly expands.",
                "category": "company",
                "datetime": 1788287337,
                "headline": "Novo Nordisk Trades Nearly 58% Below GF Value as Wegovy Pill Launches in Germany"
              },
              {
                "id": 141369812,
                "url": "https://finnhub.io/api/news?id=ebd7a8f25257402a2a2fed29a89696330649006797da39c623f94590dbe226b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "LLY's $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas.",
                "category": "company",
                "datetime": 1788286200,
                "headline": "Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal"
              },
              {
                "id": 141369810,
                "url": "https://finnhub.io/api/news?id=9c47d92de358075c05db8cfe756c5d53be8d053be6b12945e2f0460f99b4795e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Employer coverage of GLP-1 drugs is collapsing heading into 2027, but the FDA just gave Eli Lilly a specific piece of ammunition that could change the conversation in payer meetings for at least one slice of that market.",
                "category": "company",
                "datetime": 1788277213,
                "headline": "Insurers Are Pulling Back From GLP-1 Drugs. The FDA Just Handed Eli Lilly Its Best Weapon Yet"
              },
              {
                "id": 141360810,
                "url": "https://finnhub.io/api/news?id=67c1689f176b9556f0173351027b291e3ed2d66b0af49b2d484b97dceaaea99f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. Ilya Yuffa, executive vice president and president, Lilly USA and Global Customer Capabilities, will take part in a fireside chat at 1:50 p.m. Eastern time.",
                "category": "company",
                "datetime": 1788274800,
                "headline": "Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference"
              },
              {
                "id": 141360827,
                "url": "https://finnhub.io/api/news?id=59f156868ac7b9423ef388b02aa29bf66e03e13e0c5da7f989326c379febef36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.",
                "category": "company",
                "datetime": 1788273780,
                "headline": "GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit?"
              },
              {
                "id": 141370499,
                "url": "https://finnhub.io/api/news?id=449bfd73faa2a0619ff0244e90ac9f9188892e5b55be042037046fe31ded0beb",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss",
                "category": "company",
                "datetime": 1788271464,
                "headline": "FDA Says It Has Received 990 Adverse Event Reports Tied To Compounded Semaglutide And More Than 730 Tied To Compounded Tirzepatide; Establishes Import Alert For Compounded GLP-1 Active Pharmaceutical Ingredients"
              },
              {
                "id": 141360811,
                "url": "https://finnhub.io/api/news?id=a1f104c3eed67391ce32d2481aac2b51ac1441afa4355422bc7afdfdddc7f243",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.",
                "category": "company",
                "datetime": 1788270346,
                "headline": "Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly’s GLP-1 Drugs"
              },
              {
                "id": 141360812,
                "url": "https://finnhub.io/api/news?id=ab2ef9a9cc4a806b3b480659894b34248afe03e82096e10ca20c05b98ba6eeee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Merida's lead programme, MER511, is in Phase I development for Graves' disease and thyroid eye disease (TED).",
                "category": "company",
                "datetime": 1788264913,
                "headline": "Eli Lilly continues near-monthly M&A presence with $2.9bn Merida deal"
              },
              {
                "id": 141360813,
                "url": "https://finnhub.io/api/news?id=03c6d36651402c0ae5f7b3fa0a2a0405e39f985613d56c96dcf079768d02c8f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Retail traders viewed the Merida acquisition as evidence that Big Pharma will pay rich premiums for immune-focused platforms.",
                "category": "company",
                "datetime": 1788246569,
                "headline": "SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’"
              },
              {
                "id": 141360814,
                "url": "https://finnhub.io/api/news?id=d78b2e58bb4df69d9df271d22ca4885ba9487ded94bff33fd40e0f820e0d9977",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The milestone-heavy purchase adds a broad scientific platform, but its lead medicine remains at the earliest clinical stage.",
                "category": "company",
                "datetime": 1788234587,
                "headline": "Lilly's $2.88 Billion Immunology Deal Starts in Phase 1"
              },
              {
                "id": 141360815,
                "url": "https://finnhub.io/api/news?id=18dd773d1bd7812973b44b469a47d05c7eb203d6254d208dc8de410c6f3e223e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE:LLY) has agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and milestone-based payments. The deal is expected to close in the fourth quarter of 2026. The acquisition expands Lilly’s immunology pipeline and gives it access to Merida’s antibody-engineering platform, which is […]",
                "category": "company",
                "datetime": 1788223475,
                "headline": "Eli Lilly (LLY) Makes a $2.88 Billion Autoimmune Bet. What Could Go Right or Wrong?"
              },
              {
                "id": 141360828,
                "url": "https://finnhub.io/api/news?id=28c2d62223d73d68b59ad1d81c7fd873fd5841d47ee6c8b1683b66f5d67e1ba4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "By Karen Roman Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company). Mr. Benecchi will lead the company’s operational side as Inventiva comes close to its NATiV3 Phase 3 study results of lanifibranor in MASH, expected for […] The post Chris Benecchi Named Inventiva’s New Chief Operating Officer appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1788217694,
                "headline": "Chris Benecchi Named Inventiva’s New Chief Operating Officer"
              },
              {
                "id": 141360816,
                "url": "https://finnhub.io/api/news?id=867898558499a76564ebd5dedeb3ff9af7dc50fe9a8949f1336b0246448eb222",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Hardly for the first time recently, the company is making a pricey acquisition.",
                "category": "company",
                "datetime": 1788217310,
                "headline": "Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors."
              },
              {
                "id": 141360817,
                "url": "https://finnhub.io/api/news?id=da8bbc33bf96b7e157a8767877bdf08e2b6e5d96b9fb0ffc0e1c0146db8a7f6a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index decreasing 0.5% a",
                "category": "company",
                "datetime": 1788209777,
                "headline": "Sector Update: Healthcare Stocks Decline Late Afternoon"
              },
              {
                "id": 141360818,
                "url": "https://finnhub.io/api/news?id=90bbda17ec6bb872e54682e5096bd58ef6cea58ed38b56025dbe3ead688c0310",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly agrees to acquire Merida Biosciences, the developer of autoimmune drugs, marking the latest move to bolster its portfolio through strategic acquisitions.",
                "category": "company",
                "datetime": 1788206880,
                "headline": "Lilly Is Bigger Than Ever. Why Its Latest $2.9 Billion Immunology Deal Makes Sense."
              },
              {
                "id": 141360819,
                "url": "https://finnhub.io/api/news?id=8cd7b94413aede87109cc6638de18cf30d1e5c21c22ed31d65113a4e24705c45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly announced a $2.88 billion acquisition of Merida Biosciences. Here’s what it means for LLY shares.",
                "category": "company",
                "datetime": 1788204503,
                "headline": "A $2.88 Billion Reason Why Eli Lilly Stock Is in Focus Today"
              },
              {
                "id": 141360826,
                "url": "https://finnhub.io/api/news?id=09e84ae54d907002bcf896f4ba42be34c6b4adbea76de361ec536be0891a2229",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "OpenAI just built an AI-designed chip that already beats Nvidia's best in early tests, and one macro investor has pinpointed exactly when Nvidia's most valuable competitive advantage disappears entirely.",
                "category": "company",
                "datetime": 1788204012,
                "headline": "Nvidia’s Scarcity Runs Out in Five Years: ‘A Chip Designed by OpenAI, by AI’"
              },
              {
                "id": 141360820,
                "url": "https://finnhub.io/api/news?id=1df0df20de7aabb85df09fc4c34c5731bfc6fe40781bd266d3afd73797d03fb2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a very different yield story.",
                "category": "company",
                "datetime": 1788202928,
                "headline": "This Popular Healthcare ETF Is Diluting Your Dividend Income"
              },
              {
                "id": 141360821,
                "url": "https://finnhub.io/api/news?id=1cc54841b007caffc048f9790ccf41e6265548912f70b5576adba6e79db5fc4e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "In an interview with CNBC, CEO David Ricks said the company’s long-term strategy includes making its obesity franchise more durable and investing in technologies to transform the treatment of other diseases.",
                "category": "company",
                "datetime": 1788202538,
                "headline": "Eli Lilly CEO Says $25B Deal Spree Is About Building Growth Beyond Obesity Into 2030s — ‘Not All These Bets Will Pay Off’"
              },
              {
                "id": 141360822,
                "url": "https://finnhub.io/api/news?id=41a34d4f3677c8071f074a2cf7db7568f27f74fa71c1507ee4a8373348329dbe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly stock has delivered very strong gains over the past five years. Current checks give a mixed read on valuation, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside, while market based multiples look closer to fair. Eli Lilly has returned 373.6% over five years, which puts a lot of optimism into the share price and raises the bar for what counts as good value today. The expanded use of drugs like Mounjaro and Zepbound in metabolic and cardiovascular care...",
                "category": "company",
                "datetime": 1788199467,
                "headline": "Eli Lilly (LLY) Stock May Be 30% Undervalued Despite Fresh FDA Approval"
              },
              {
                "id": 141360823,
                "url": "https://finnhub.io/api/news?id=becb26c93f05a80f6591160fc71090a4e96b4c880a7253ac37df2df4a2e87866",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly Stock Slides as Pharma Giant Strikes $2.9 Billion Merida Deal",
                "category": "company",
                "datetime": 1788197479,
                "headline": "Eli Lilly Stock Falls After Pharma Giant Unveils $2.9 Billion Acquisition"
              },
              {
                "id": 141368783,
                "url": "https://finnhub.io/api/news?id=c84210751a276abc7fb452ed72d8204e1aaf094cf9548503ed01e058119a23a7",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "As previously disclosed, AtaiBeckley Inc. (the "Company") entered into an Agreement and Plan of Merger, dated as of July 15, 2026 (the "Merger Agreement"), with Eli Lilly and Company, an Indiana",
                "category": "company",
                "datetime": 1788194563,
                "headline": "AtaiBeckley Says Hart-Scott-Rodino Waiting Period For Merger With Eli Lilly Expired On Aug 28, 2026; UK Competition Authority Has No Further Questions On Merger As Of August 21, 2026"
              },
              {
                "id": 141360824,
                "url": "https://finnhub.io/api/news?id=a2950d9f9d750a17acd9a7b522e30b9755e639244d89cd3fb9dcbd536949edff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The Merida acquisition adds an early-stage autoimmune platform as Lilly broadens its pipeline.",
                "category": "company",
                "datetime": 1788193931,
                "headline": "Eli Lilly's Next $2.9 Billion Bet Is Not About Obesity"
              },
              {
                "id": 141360825,
                "url": "https://finnhub.io/api/news?id=afeb7f43fd24f3559181a31e956a3d0d4f5b93b28e32124da706cfdb34c6ccff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Co (NYSE:LLY) said on Monday it will acquire privately held Merida Biosciences for up to $2.88 billion in cash, part of a deal-making push to broaden its treatments for immune-related and allergic diseases. The acquisition continues a run of dealmaking for Lilly, whose deal...",
                "category": "company",
                "datetime": 1788192480,
                "headline": "Eli Lilly to buy Merida Biosciences for up to $2.88B, expanding immunology pipeline"
              },
              {
                "id": 141356225,
                "url": "https://finnhub.io/api/news?id=59a441525d8351f9ca682906e1f1184af38874463dd1c92a51d84c67a55ae7f7",
                "image": "",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "",
                "category": "company",
                "datetime": 1788188253,
                "headline": "Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know"
              },
              {
                "id": 141355595,
                "url": "https://finnhub.io/api/news?id=8895fcfcf8d3d1190b2607a238127bac333af14caed7224e7640cfb9982341e8",
                "image": "https://image.cnbcfm.com/api/v1/image/108211777-17604496412025-10-14t130306z_1505683512_rc2zlgawdylw_rtrmadp_0_tech-broadcom-chips.jpeg?v=1760449701&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "\"The stakes are high\" heading into Broadcom earnings, says Mike Khouw.",
                "category": "company",
                "datetime": 1788182295,
                "headline": "Broadcom reports earnings this week. Mike Khouw says this trade could be a winner"
              },
              {
                "id": 141355772,
                "url": "https://finnhub.io/api/news?id=6bbd17c3d37ccacbc2173c752d2a71f9997bdbafacfef53e43a34283cbfb1616",
                "image": "https://image.cnbcfm.com/api/v1/image/107265682-1688164253580-GettyImages-1367403983.jpg?v=1694132041&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "These are some of the stocks posting the largest moves midday.",
                "category": "company",
                "datetime": 1788181044,
                "headline": "Stocks making the biggest moves midday: PG&E, Edison International, Apple, Howmet Aerospace, Eli Lilly & more "
              },
              {
                "id": 141355051,
                "url": "https://finnhub.io/api/news?id=d92b169b63df4d431d6ca4d3e2a910e2a44404564eff749693f603b009075ae3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/466613278/image_466613278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.",
                "category": "company",
                "datetime": 1788173434,
                "headline": "Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs"
              },
              {
                "id": 141355770,
                "url": "https://finnhub.io/api/news?id=4c36b064a7456dc98276f7a3ff1c9f3658d6cc8b385e1ed5d5ea757523db0dcf",
                "image": "https://image.cnbcfm.com/api/v1/image/108356391-1788185075641-gettyimages-2292361187-AFP_C6WX2WK.jpeg?v=1788185127&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "This is CNBC's live blog of the U.S. G20 finance ministerial in Asheville, North Carolina. Please check back for updates.",
                "category": "company",
                "datetime": 1788166374,
                "headline": "G20 meeting live updates: Bessent, Warsh kick off summit with growth-focused remarks"
              },
              {
                "id": 141356706,
                "url": "https://finnhub.io/api/news?id=809bb23fab160f3c60b7ab026e6a7da2497652be2ce493ef10ad51c0cbbee1fc",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "At Week 52, Taltz and Zepbound maintained or further improved psoriasis or psoriatic arthritis disease activity from Week 36, when statistically superior improvements versus Taltz alone were observed in the TOGETHER-PsO",
                "category": "company",
                "datetime": 1788159977,
                "headline": "Eli Lilly Says 52-Week Data from TOGETHER-PsO and TOGETHER-PsA Phase 3b trials of the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) Vs. Taltz Alone Shows Improved and Durable Efficacy in Patients With Psoriatic Disease and Obesity"
              },
              {
                "id": 141356707,
                "url": "https://finnhub.io/api/news?id=5f33d56823647a45bd4c282ede22de8d473161276336b1e3b8172c08571a7da7",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Merida's antibody-engineering platform is designed to enable precise, durable removal of disease-causing antibodies, while preserving normal immune functionInitial Phase 1 data show MER511 achieved robust reductions",
                "category": "company",
                "datetime": 1788158850,
                "headline": "Eli Lilly To Acquire Merida And Pay Up To $2.875B In Cash; Transaction Expected To Close In Q4 2026"
              },
              {
                "id": 141353592,
                "url": "https://finnhub.io/api/news?id=0ae9a1d3a0beae67517a710851faaa174dc3df55c6700854d8d749aa1af9e1f5",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2290518089/image_2290518089.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Hims & Hers Health is building a vertically integrated consumer health distribution platform. Read why I am bullish about HIMS stock right now.",
                "category": "company",
                "datetime": 1788154508,
                "headline": "Hims & Hers: A Healthcare Behemoth In The Making"
              },
              {
                "id": 141338178,
                "url": "https://finnhub.io/api/news?id=cb6cbf4f68c449a8f130c647131401fd9b0c4534d5903f8a98a85ae67f4ba84c",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Mounjaro is the first and only GIP and GLP-1 receptor agonist proven to lower heart attack, stroke or cardiovascular death risk in adults with type 2 diabetes at high risk for these events – in addition to its",
                "category": "company",
                "datetime": 1787900594,
                "headline": "Eli Lilly Says FDA Approves Mounjaro, Dual GIP And GLP-1 Hormone Receptor Agonist, To Lower Risk Of Major Adverse Cardiovascular Events In Adults With Type 2 Diabetes"
              },
              {
                "id": 141331774,
                "url": "https://finnhub.io/api/news?id=d7194a9139addd40e694b10090467418e2036cc2fa63ab68abe4180d8e55ece8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2291247256/image_2291247256.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Biohaven Ltd. maintains a Buy rating, driven by pivotal trial progress in protein degraders and a key licensing deal for its Kv7 platform. Click here for more.",
                "category": "company",
                "datetime": 1787840471,
                "headline": "Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More"
              },
              {
                "id": 141324624,
                "url": "https://finnhub.io/api/news?id=4fcee419bb1380be82bafd38daa6f2c25af915bc8e8c463bd2166be88758354d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session.",
                "category": "company",
                "datetime": 1787771101,
                "headline": "What's going on in today's session: S&P500 movers"
              },
              {
                "id": 141332583,
                "url": "https://finnhub.io/api/news?id=af7b54569dca086bb3a305a5fa422cbfcb2de4ead3840ccbd047df91388b861a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/26/Zepbound.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "New Eli Lilly study reveals that Zepbound significantly lowers monthly healthcare costs for older adults with overweight or obesity.",
                "category": "company",
                "datetime": 1787758219,
                "headline": "Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs"
              },
              {
                "id": 141332584,
                "url": "https://finnhub.io/api/news?id=2417c6dbc1a69196f6ec518fb56836f7b71b7e586841422dd3d244ecae668de7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/26/Eli-Lilly-Logo.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly and Co. shares are trading lower Wednesday, pulling back from last week's record high despite positive real-world data on Zepbound.",
                "category": "company",
                "datetime": 1787755202,
                "headline": "Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week"
              },
              {
                "id": 141324019,
                "url": "https://finnhub.io/api/news?id=93693e522727c16ce265ecaefe78c970775937a2523bdf51c209f1a64665f5fb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359528534/image_1359528534.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Meta Platforms (META) has reached a settlement with state attorneys general over allegations that Facebook and Instagram were intentionally designed to be addictive to minors.",
                "category": "company",
                "datetime": 1787750700,
                "headline": "Wall Street Lunch: Meta Settles Minors' Addiction, Data Privacy Claims For $12.7B"
              },
              {
                "id": 141323960,
                "url": "https://finnhub.io/api/news?id=cf087cbfcf6442c6f145fa7516f2c7ae3657b296cc038e226f8f91a561b7c4f8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/26/Stocks-Fall--Technology-Businesses-Do-No.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Nasdaq 100 falls 0.6% as traders wait on Nvidia and hot July PCE revives September rate-hike bets. Energy leads, gold sinks 1.3% to $4,599.",
                "category": "company",
                "datetime": 1787749114,
                "headline": "Nasdaq 100 Falls as Hot PCE Inflation Stirs Rate-Hike Bets: Stock Market Today"
              },
              {
                "id": 141322667,
                "url": "https://finnhub.io/api/news?id=5c5edd881f8ff46b5ffb2af11468ec1719653221bcfc775af7a174f9b8bb2db6",
                "image": "https://www.chartmill.com/images/uploads/thumbnail_article_o_neill_9796d922cc.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) passes the CAN SLIM screen with strong earnings, sales growth, high relative strength, and bullish technicals. Learn more.",
                "category": "company",
                "datetime": 1787748069,
                "headline": "Eli Lilly (NYSE:LLY) Demonstrates High-Growth Leadership and Momentum"
              },
              {
                "id": 141323377,
                "url": "https://finnhub.io/api/news?id=56e3a8a0f81159bcc19d0c2af1f567f2aa84f668671d90793e85ea8c670735bf",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "An official report on August 25, 2026 reveals Representative Michael Rulli's recent sale of Alphabet (NASDAQ:GOOGL) stock, valued between $50,001 and $100,000. The transaction took place on August 24, 2026, as per",
                "category": "company",
                "datetime": 1787742083,
                "headline": "Ohio Rep. Michael Rulli Sold Up to $100K Worth of Alphabet Stock"
              },
              {
                "id": 141323348,
                "url": "https://finnhub.io/api/news?id=0dbcfc30635e0f9698ddfc682796ff62288ca4417dd20d700abe0697a0b6b74f",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "For adults over the age of 55, including patients in Medicare's GLP-1 Bridge program, these lower costs translate into meaningful savings as early as 12 months into treatment. This is the first study of its kind in",
                "category": "company",
                "datetime": 1787726863,
                "headline": "Eli Lilly Announces Results From Real-World Study Of Overweight Or Obese Adults Over 55 Indicating That Staying On Zepbound For Weight Management Lowered Healthcare Costs Over Time"
              },
              {
                "id": 141308255,
                "url": "https://finnhub.io/api/news?id=b3d2bc035a5d0b3ae93a25dd5c441271a5816a854e89c457781877b1b020e1ba",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "LLY offers a modest 0.75% yield but a sustainable 7/10 dividend rating, 15% annual growth, and a 21.66% payout ratio, backed by strong profitability.",
                "category": "company",
                "datetime": 1787574710,
                "headline": "Eli Lilly (NYSE:LLY): A Dividend Quality Pick with Sustainable Growth"
              },
              {
                "id": 141308361,
                "url": "https://finnhub.io/api/news?id=398dc1bb1afe1cde50b49a34f4eb32c0d0624e17eb7abcf2c4a586531bb02b3b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novo Nordisk (NVO) may be bottoming as LLY share losses stabilize; trading ~15x forward earnings with catalysts like Wegovy pill & CagriSema.",
                "category": "company",
                "datetime": 1787562000,
                "headline": "Novo Nordisk: Don't Ignore This Dirt-Cheap Buying Opportunity"
              },
              {
                "id": 141308324,
                "url": "https://finnhub.io/api/news?id=d230e0ece83f4cba236cd869d85db24371c89847d296e0eca3524ccfa078799b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1419068069/image_1419068069.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Sanofi stock faces temporary pressure after Trump’s vaccine order, but trades cheap (9.2x P/E) with raised 2026 guidance. Click for this SNY update.",
                "category": "company",
                "datetime": 1787561537,
                "headline": "Sanofi: Trump's Vaccine Policy Won't Break The Story"
              },
              {
                "id": 141310757,
                "url": "https://finnhub.io/api/news?id=b3aed2a62b36ca9bff08c706276bb1e615b51b563dccc1170bc9ce0ba209cb13",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "-Reuters",
                "category": "company",
                "datetime": 1787542931,
                "headline": "Eli Lilly Makes Foundayo Available To Eligible UK Adults Privately, Seeks NICE Assessment For NHS Use At £100-£120 Pricing"
              },
              {
                "id": 141302531,
                "url": "https://finnhub.io/api/news?id=2cc15de1e342b93f1401b5077083d5881f0e6f7a954a6da86576b6e2e6d3a8b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly just delivered one of the most staggering quarters in Big Pharma history, yet Wall Street is barely reacting. Three catalysts in the next 18 months could either push shares to levels few analysts dare to print or expose the cracks in a very expensive story.",
                "category": "company",
                "datetime": 1787504411,
                "headline": "Prediction: Eli Lilly Could Be One of the Biggest Winners of the Next Decade. Here’s Why."
              },
              {
                "id": 141302632,
                "url": "https://finnhub.io/api/news?id=d50f9c82ee6494ab64621b293f0ec67a0674b0ed76e651546a532cfbeba7f043",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Griffin's Q2 move is already paying off nicely.",
                "category": "company",
                "datetime": 1787479440,
                "headline": "Billionaire Ken Griffin Just Loaded Up on Eli Lilly Stock. Should You?"
              },
              {
                "id": 141302633,
                "url": "https://finnhub.io/api/news?id=710f3c3ca6e342bdec112e491629522821f6eb5c5c8bf1a9882b2cb278aa4676",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.",
                "category": "company",
                "datetime": 1787415000,
                "headline": "2 Biotech Stocks Shaping Up for Major Breakouts"
              },
              {
                "id": 141293866,
                "url": "https://finnhub.io/api/news?id=c0ba664bc76fd0b5e7cfdf71ef6519140d1d4a9d602654490b9d8d775db86acc",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1414474713/image_1414474713.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) leads the global obesity drug market vs Novo Nordisk as competition heats up.",
                "category": "company",
                "datetime": 1787395890,
                "headline": "Eli Lilly: Shaking Off Competition From The Dethroned Novo Nordisk"
              },
              {
                "id": 141278026,
                "url": "https://finnhub.io/api/news?id=b93758b0686d52656cb855fada506016ded212288e3d38d64d7255fb25b034b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Veeva Systems recently secured Eli Lilly and Company’s commitment to deploy Veeva Vault CRM globally, while also announcing that President and Chief Customer Officer Thomas D. Schwenger will depart in October 2026, to be succeeded by Dan Rizzo as EVP of Sales, Consulting, and Services. These developments arrive as Wall Street analysts anticipate higher upcoming quarterly earnings and revenue for Veeva, highlighting how large client wins and leadership transitions could shape the company’s...",
                "category": "company",
                "datetime": 1787389731,
                "headline": "Will Eli Lilly’s Global Vault CRM Deal and Leadership Shift Change Veeva Systems’ (VEEV) Narrative?"
              },
              {
                "id": 141282175,
                "url": "https://finnhub.io/api/news?id=a49a6e73e1aeceed0ffd3246f8930654ebd09edea198f76ef780e38deb2feff7",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1177165160/image_1177165160.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Read about our data-driven method to pick high-growth dividend stocks focused on sustainable dividend growth, plus the top 10 picks this month.",
                "category": "company",
                "datetime": 1787386800,
                "headline": "Our Top 10 High Growth Dividend Stocks - August 2026"
              },
              {
                "id": 141282187,
                "url": "https://finnhub.io/api/news?id=0cbcff8caf58cbcfbfc47128930be73edbbd176eb424c7737c0049545a204699",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/885294104/image_885294104.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Explore First Trust Enhanced Equity Income Fund: 6.67% yield via covered calls, tech-heavy risks, discount to NAV, performance vs. S&P 500. Click to read more.",
                "category": "company",
                "datetime": 1787386692,
                "headline": "FFA: Beware Of The AI Risk With This High-Yielding Covered Call Fund"
              },
              {
                "id": 141278027,
                "url": "https://finnhub.io/api/news?id=9451b95235bc398935ffd268047682b156afbc25046b8e7a4986065f6d706a9c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly recently reported strong revenue growth driven by its Mounjaro and Zepbound obesity and diabetes drugs, raised full-year guidance, advanced its next-generation GLP-1 pipeline, and secured UK approval for Foundayo, its once-daily oral GLP-1 pill for weight management and type 2 diabetes. These developments, alongside vaccine research collaborations and ongoing legal action against unauthorized retatrutide sellers, highlight Lilly’s bid to extend its leadership across injectable,...",
                "category": "company",
                "datetime": 1787375897,
                "headline": "Eli Lilly (LLY) Is Up 6.4% After UK Clears Foundayo and GLP‑1 Portfolio Advances - What's Changed"
              },
              {
                "id": 141278036,
                "url": "https://finnhub.io/api/news?id=c0acd15c497b3e71b58cf211db92a739c50e66b038a6889ccbf7a4e6fd48b035",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Drugmaker Bristol-Myers Squibb Company (NYSE:BMY) is putting real money behind its confidence in American manufacturing. On August 10, the company said it will spend about $2.3 billion on a new plant in Houston, part of a larger $40 billion U.S. investment pledge. On the very same day, British regulators cleared Eli Lilly and Company (NYSE:LLY)’s […]",
                "category": "company",
                "datetime": 1787344082,
                "headline": "Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK"
              },
              {
                "id": 141296611,
                "url": "https://finnhub.io/api/news?id=69c664c945081e8a295d1cf4192cae38ef1dfb2769871127031cb3470b9f8280",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Mounjaro and Zepbound are widening Lilly's advantage while its next-generation pipeline adds fresh growth options.",
                "category": "company",
                "datetime": 1787342594,
                "headline": "Eli Lilly Jumps as Weight-Loss Leadership Drives Another Breakout"
              },
              {
                "id": 141278028,
                "url": "https://finnhub.io/api/news?id=b85cf2c4c1752d6b68a87ce0e31deed248fb731b2165e96279cc313ac08ca183",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Consensus asks Eli Lilly for far less growth than it is delivering, and for margins to keep climbing from a level it only just reached.",
                "category": "company",
                "datetime": 1787341256,
                "headline": "Lilly's Multiple Assumes Less Growth Than You Think"
              },
              {
                "id": 141274042,
                "url": "https://finnhub.io/api/news?id=2cd709299f25f69105efbea24e9a2b1361432293aa3542628ad0a84d35c6541b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238634495/image_2238634495.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Novo Nordisk A/S stays a Buy as oral Wegovy surges and GLP-1 pipeline strengthens; attractive 2028 P/E suggests upside—click to read the NVO stock outlook now.",
                "category": "company",
                "datetime": 1787338231,
                "headline": "Novo Nordisk: The Pill That Could Close The Gap With Lilly"
              },
              {
                "id": 141278037,
                "url": "https://finnhub.io/api/news?id=2171816a642cf2107b69f459ff8b534241a7636c5e34d5621c3285981f97c7b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "What AbbVie sells, and who pays for it, is the useful way to read its low correlation to the index.",
                "category": "company",
                "datetime": 1787338129,
                "headline": "Most Of What Moves AbbVie Stock Has Nothing To Do With The Market"
              },
              {
                "id": 141297696,
                "url": "https://finnhub.io/api/news?id=133ef4466679e64bc76d753b0dbe55433474a8d077f1303e4abffdce265f2481",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 25.41% on an annualized basis producing an average annual return of 36.72%. Currently, Eli Lilly has a market capitalization of $1.12 trillion.",
                "category": "company",
                "datetime": 1787335239,
                "headline": "Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 5 Years"
              },
              {
                "id": 141272877,
                "url": "https://finnhub.io/api/news?id=3391283ffa748b939e5d09f2e48386c5cd2beb9505dded9bccf4b7d8d1fe5ce3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2290019208/image_2290019208.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Buy ProQR Therapeutics N.V.: Axiomer RNA editing shows strong phase 1 proof-of-concept for biliary atresia; key 2026–27 catalysts ahead. Click to read more.",
                "category": "company",
                "datetime": 1787330932,
                "headline": "ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts"
              },
              {
                "id": 141278029,
                "url": "https://finnhub.io/api/news?id=b3b7124e11c804eb8b33e233182c0120980b706347010f70e6f2c801dafa525d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Shares recently traded at $1,280 each, so a split wouldn't be surprising.",
                "category": "company",
                "datetime": 1787328300,
                "headline": "Stock Split Watch: Is Eli Lilly (LLY) Stock Next?"
              },
              {
                "id": 141271580,
                "url": "https://finnhub.io/api/news?id=852d8a6f9219f4009d3146ea143a2d4f2e5355f1700e8eae88e15c543d5ec590",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1787319319,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141278038,
                "url": "https://finnhub.io/api/news?id=a1449eb62beaa306a2349f225d54d4e5ac75442076b5040e88b3d0c9bcba1043",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Apple paid Ireland $17bn in taxes last year, representing 40 per cent of its worldwide total, according to filings that offer new insight into...",
                "category": "company",
                "datetime": 1787319263,
                "headline": "Apple paid $17bn in taxes to Ireland after court ruling on back levies"
              },
              {
                "id": 141278039,
                "url": "https://finnhub.io/api/news?id=e68f6a3a542ae07d07afd9a4c2837484ae1d71fbd4f4419f681e7005fbb1abf7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The  exchange-traded fund, home to some large pharma companies and many smaller biotechs, has risen over 6% this week.  The main catalyst was  Moderna  and  Merck  announcement of  successful trial data for a melanoma vaccine that reduces the risk patients will experience recurrence.  “The read-through [from Merck and Moderna] to the others is probably indicative of a broader tailwind of pharma taking some strong actions to improve their long-term growth profiles,” says Cantor Fitzgerald analyst Carter Gould.",
                "category": "company",
                "datetime": 1787317680,
                "headline": "Pharma Stocks Have Rallied. 2 Stocks to Avoid—and 2 to Buy."
              },
              {
                "id": 141278040,
                "url": "https://finnhub.io/api/news?id=34da1995f5dc456a17a28f00f7c291afa4ede93d426b544d3380cb82a92e80e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly stock broke out of a flat base and reached a record high. Its Mounjaro drug sales surged 91% in the second quarter.",
                "category": "company",
                "datetime": 1787317242,
                "headline": "Eli Lilly Is In A Race with Novo Nordisk But Its Stock Is The Clear Winner"
              },
              {
                "id": 141269403,
                "url": "https://finnhub.io/api/news?id=04f4d7d2c6e06ef35b8e6baebfcc823c2f41adff8f518297db85e6996f89b8d0",
                "image": "https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) shines as a strong-growth stock with explosive earnings, high profitability, and a bullish breakout technical setup.",
                "category": "company",
                "datetime": 1787311279,
                "headline": "Eli Lilly (NYSE:LLY) Shows Strong Growth and a Compelling Technical Setup"
              },
              {
                "id": 141278031,
                "url": "https://finnhub.io/api/news?id=cb80cfe11718f7fa6c24e780b8257839be017667ee47bddcd716bbc3e46f2696",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Kaos Capital wants a “governance reset” to alter the Duchenne cell therapy maker’s strategic course. Elsewhere, Bristol Myers furthered efforts to build an “AI-powered” discovery engine.",
                "category": "company",
                "datetime": 1787308200,
                "headline": "Shareholder pressures Capricor; Lilly dives deeper into vaccines"
              },
              {
                "id": 141269649,
                "url": "https://finnhub.io/api/news?id=25595542c954f854dc850eb0078ca0894ab39750efa9c25c5000303b15e24f4d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1339660797/image_1339660797.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Direct indexing is rising fast: build an 11-stock, sector-matched S&P 500-style portfolio and boost after-tax returns with tax-loss harvesting. Read more here.",
                "category": "company",
                "datetime": 1787301026,
                "headline": "$1 Million In The S&P 500: An 11-Stock Direct Indexing Strategy"
              },
              {
                "id": 141278032,
                "url": "https://finnhub.io/api/news?id=f4e8013148b04b76a987d48f3bb854941d045616802bd9d5d70e947dbb85b8dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Can anyone challenge Eli Lilly in the weight loss space?",
                "category": "company",
                "datetime": 1787263501,
                "headline": "There’s a Black Market for Eli Lilly’s Unapproved GLP-1 Drug. Here’s Why That’s Bullish"
              },
              {
                "id": 141278033,
                "url": "https://finnhub.io/api/news?id=17e8018e986f46c228db17a735f625ef7fa69b7ea52cc0db3d90f3696dda0410",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Investors took profits after record highs, but Mounjaro and Zepbound continue producing extraordinary growth.",
                "category": "company",
                "datetime": 1787257162,
                "headline": "Eli Lilly Slips After Crossing $1.1 Trillion"
              },
              {
                "id": 141278034,
                "url": "https://finnhub.io/api/news?id=5102ef59b5fee5ff39b19c8732956402bfb05bc1f56ae621bd6ee687a55021b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) is back in focus after the UK's Medicines and Healthcare products Regulatory Agency approved Foundayo, a once daily oral GLP-1 drug for weight management and type 2 diabetes. See our latest analysis for Eli Lilly. The Foundayo approval arrives during a strong run for Eli Lilly’s stock, with a 30 day share price return of 11.63% and a year to date share price return of 18.51%. Over the longer term, total shareholder returns of 82.64% over one year and 136.19% over three years...",
                "category": "company",
                "datetime": 1787256592,
                "headline": "Is Eli Lilly (LLY) Undervalued On UK Foundayo Approval?"
              },
              {
                "id": 141278041,
                "url": "https://finnhub.io/api/news?id=b6b8b6bb83ce7842471b2d3ff17fd226a74f65641d1cab1c940ba182d5fc7a99",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The products meant to offset the KEYTRUDA patent expiry were named, and two were already booking revenue, before the stock moved.",
                "category": "company",
                "datetime": 1787250436,
                "headline": "Merck Stock Ran On A Checklist Published In Advance"
              },
              {
                "id": 141278042,
                "url": "https://finnhub.io/api/news?id=a185f67366da2df6e04ff21b866c03090a3bb454dfce33b84acf2978013b48e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its expiring patents will take away.",
                "category": "company",
                "datetime": 1787248494,
                "headline": "Pfizer Stock Is A Race Between New Drugs And Old Patents"
              },
              {
                "id": 141278043,
                "url": "https://finnhub.io/api/news?id=1557931c3a9c8a09df480a39a0373503f28ba9c14f961b26e8249ae8e804594b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "NVO's U.S. launch of Awiqli introduces the first once-weekly basal insulin, potentially giving the company a new growth opportunity beyond its pressured GLP-1 franchise.",
                "category": "company",
                "datetime": 1787239140,
                "headline": "Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s?"
              },
              {
                "id": 141278035,
                "url": "https://finnhub.io/api/news?id=e8ec7a4f853a1e545ea85b1043f26ebed43c73a1564a672fa599b0741026a870",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Dow Jones futures: Crude oil continues to climb while bitcoin jumped again amid a weak dollar. Walmart earnings are in focus.",
                "category": "company",
                "datetime": 1787231760,
                "headline": "Dow Jones Futures Fall As Oil Prices, Bitcoin Jump; Walmart Skids On Earnings"
              },
              {
                "id": 141263972,
                "url": "https://finnhub.io/api/news?id=c214f7edde73e38268c28f3292e33e368242c402dff0bce82285ce82ed18e751",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "You do not expect a pharmaceutical giant with a $376 billion market cap to put up numbers that make growth investors blush. Yet over the last 12 months, Merck (MRK) handed investors an 80% return, lapping the S&P 500. The apex occurred yesterday, August 19, 2026, when the stock surged to all-time highs.",
                "category": "company",
                "datetime": 1787223588,
                "headline": "Why Is Merck Stock Still Undervalued After An 80% Surge?"
              },
              {
                "id": 141262039,
                "url": "https://finnhub.io/api/news?id=d209f8d1cd473fe3476d9967700e9a22635d6821755b8f5784f3c87ab02146b9",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Amplitude Therapeutics, a biotechnology company developing trans-amplifying RNA (taRNA) medicines and vaccines, today announced a strategic research collaboration and licensing agreement with Eli Lilly and Company",
                "category": "company",
                "datetime": 1787153574,
                "headline": "Amplitude Therapeutics Partners With Eli Lilly Over Discovery, Development Of taRNA Vaccine Candidates For Infectious Diseases"
              },
              {
                "id": 141255594,
                "url": "https://finnhub.io/api/news?id=3be879eac62e53b8c7ea7ac790ed318cfb5727f57f7db7b32c3dc2c47c2f3ada",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Silence Therapeutics rises on trial results and funding updates; Read on to see Divesiran’s outlook vs. Takeda’s rusfertide competition and analyst views.",
                "category": "company",
                "datetime": 1787152436,
                "headline": "Silence Therapeutics: Making Some Recent Noise"
              },
              {
                "id": 141254920,
                "url": "https://finnhub.io/api/news?id=e89c64709ddd6a7995aae1754791a3f6d88481af9be88c0efb732c183203d1e2",
                "image": "",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "",
                "category": "company",
                "datetime": 1787148432,
                "headline": "Novo Nordisk: The Best Value In Pharma"
              },
              {
                "id": 141253881,
                "url": "https://finnhub.io/api/news?id=40d0dc36eaffbf7f2dddc10fc9074ea75de80d9df3b566c59606cdb6b5eb3a5a",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "https://www.wsj.com/health/pharma/novo-nordisk-starts-testing-lower-doses-of-its-wegovy-weight-loss-pills-8896fec2",
                "category": "company",
                "datetime": 1787130576,
                "headline": "'Novo Nordisk Starts Testing Lower-Doses of Its Wegovy Weight-Loss Pills' - WSJ"
              },
              {
                "id": 141254221,
                "url": "https://finnhub.io/api/news?id=2b2d9a3b15ba5b6cf0faef3a0ad0ddb3551f8568d3d308a2048dc70e4fab600b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Netflix-Clause-Added.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Bryn Talkington picked Horizon Kinetics, Stephanie Link chose Elanco Animal Health, and Jason Snipe recommended Netflix.",
                "category": "company",
                "datetime": 1787125562,
                "headline": "Netflix, Eli Lilly, Elanco Animal Health And More Stock On CNBC’s ‘Final Trades’"
              },
              {
                "id": 141254222,
                "url": "https://finnhub.io/api/news?id=a0ff65d0c0e1c5396bea55d0b1b1fd1c0206f87b6a256ef3a8acbe77d94b3db1",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Healthcare-stocks.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "The health care sector's oversold stocks present buying opportunities for undervalued companies. RSI compares stock strength on up and down days, with an RSI below 30 considered oversold.",
                "category": "company",
                "datetime": 1787121004,
                "headline": "Top 3 Health Care Stocks That Could Blast Off This Month"
              },
              {
                "id": 139929915,
                "url": "https://finnhub.io/api/news?id=b79febb56b13c87a7cca143e78b5079c18f27f0b0e19568309d66e12a3a0ff7d",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "",
                "category": "company",
                "datetime": 1787058082,
                "headline": "From The ETF Professor: NFLX content deal helps SKYY, cloud computing ETF, hit high of the day. NFLX 6.6% of ETF's weight"
              },
              {
                "id": 141245483,
                "url": "https://finnhub.io/api/news?id=951577fff6b4598af45924acba5d5c33d29af9be2fa0d050345660f4d15cecdc",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962548/image_1386962548.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "OmniAb (OABI) analysis: platform scaling via Eli Lilly partnership, milestone-rich revenue outlook, 2026 cash guidance, valuation and catalysts—read now.",
                "category": "company",
                "datetime": 1787042723,
                "headline": "OmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech"
              },
              {
                "id": 141241944,
                "url": "https://finnhub.io/api/news?id=a4287291a8dcb84ce3ebc725ad7c31e200a817c55c6d9a5789eca3a2ec933b4f",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "- Reuters",
                "category": "company",
                "datetime": 1786966408,
                "headline": "Eli Lilly Canada Says Continues To Take Action To Address Promotion And Sale Of Unapproved And Illegal Retatrutide Products In Canada; Disagrees With Characterizations In Canada Revenue Agency’s Application; Will Respond Formally Through Court Process In Due Course"
              },
              {
                "id": 141239006,
                "url": "https://finnhub.io/api/news?id=23a26e276c0a00256efeeebaac3de38362c3f623a26448cad301ea1dac04d931",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/17/Eli-Lilly-And-Company-Logo-On-Dark-Backg.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "The OmniAb Lilly Deal offers up to $370 million in milestones as OABI raises its 2026 cash outlook and shares jump premarket",
                "category": "company",
                "datetime": 1786958141,
                "headline": "Why Is Omniab Stock Rallying After Eli Lilly Deal?"
              },
              {
                "id": 141239009,
                "url": "https://finnhub.io/api/news?id=d8f6157c4d6dd9512775a0ed23e26d52dcd4be99d0953e6c5efc6898342c75c2",
                "image": "",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "The therapeutic target and modality are undisclosed. ",
                "category": "company",
                "datetime": 1786946821,
                "headline": "OmniAb Announces Global Collaboration and License Agreement with Eli Lilly For New Ion Channel Program; OmniAb To Receive An Upfront Payment and Is Eligible To Receive Up to $370M In R&D and Commercial Milestone Payments"
              },
              {
                "id": 141217720,
                "url": "https://finnhub.io/api/news?id=99e33aa2065a591256fc272de51c843a3fdf258e72db683b16e06da81ba91bb0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/14/Wall-street-shutter3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Small caps hit fresh highs Friday as soft retail sales and weak sentiment stalled the S&P 500, while crude climbed and SanDisk extended its post-Investor Day run.",
                "category": "company",
                "datetime": 1786713770,
                "headline": "Russell 2000 Extends Records, SanDisk Rallies 7%: Stock Market Today"
              },
              {
                "id": 141214273,
                "url": "https://finnhub.io/api/news?id=2a95ccbe932da85654f698434dbda479e6ea5234b46e5b8331db3e1fa5e7e1c7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly’s second quarter was marked by a positive market reaction, despite the company missing Wall Street’s revenue expectations. Management credited growth in key products—especially in cardiometabolic health, oncology, and neuroscience—as drivers of performance. CEO David Ricks pointed to “robust revenue growth across all Key Products and major geographies,” noting the strength of new medicines and expansion in emerging markets. The launch of Foundayo in the U.S. and UAE, along with ongoing",
                "category": "company",
                "datetime": 1786686540,
                "headline": "5 Revealing Analyst Questions From Eli Lilly’s Q2 Earnings Call"
              },
              {
                "id": 141209366,
                "url": "https://finnhub.io/api/news?id=0e05c539a1f785acb8a36a1a019417996cc69a1143d96a4a63245b9cd255029e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo argues that differentiated treatments--not a single dominant drug--will determine its position against Eli Lilly.",
                "category": "company",
                "datetime": 1786646312,
                "headline": "Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race"
              },
              {
                "id": 141209367,
                "url": "https://finnhub.io/api/news?id=54ff49eab66c76ab883a9a89568a0912fb589f5c8a10eb1a0f17a5cd224f770e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The stock continues to look unstoppable.",
                "category": "company",
                "datetime": 1786645200,
                "headline": "Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity"
              },
              {
                "id": 141209369,
                "url": "https://finnhub.io/api/news?id=08fe9e295967b66c6304c5870ca46c032d9e358cceaafe24a440496276a8ad95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "Should Investors Buy WST as HVP Growth Meets a Premium Valuation?"
              },
              {
                "id": 141209368,
                "url": "https://finnhub.io/api/news?id=634d1975102fb1ccc220df689ce957461b9a26f983d67ca02c8169a69864b38e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.",
                "category": "company",
                "datetime": 1786643280,
                "headline": "WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story"
              },
              {
                "id": 141207922,
                "url": "https://finnhub.io/api/news?id=900668dfaf10adc67dbd6705a9908bdea32f232ae2f494ca0ef99cdd6b08a405",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "A marketing dispute could reshape a crucial competitive advantage",
                "category": "company",
                "datetime": 1786642347,
                "headline": "Novo Nordisk Escalates Weight-Loss War With Eli Lilly"
              },
              {
                "id": 141207923,
                "url": "https://finnhub.io/api/news?id=88a90702b18759d550549111dea289f1d88362148d397438d1ad60ef07c20c75",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.",
                "category": "company",
                "datetime": 1786637411,
                "headline": "The Sharpest Exchanges From ABBV's Earnings Call"
              },
              {
                "id": 141207924,
                "url": "https://finnhub.io/api/news?id=9cecc83ea19c3dbdc13421448e7dadf9e56c6d08a8212405e9fb51112388d579",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The European stock markets closed mixed in Thursday trading as The Stoxx Europe edged 0.1% lower, Ge",
                "category": "company",
                "datetime": 1786636497,
                "headline": "European Stocks Close Mixed in Thursday Trading; UK GDP Growth Slows in Q2"
              },
              {
                "id": 141206476,
                "url": "https://finnhub.io/api/news?id=e7147d197da19bc29c1974b2353a5dba9815cb705704b8354af0ffe58ac1036e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) has spent 2026 defending its lead in the weight-loss drug market, mostly with injections. That approach is changing. On Aug. 10, Britain's medicines regulator cleared Lilly's new daily pill for both weight management and type 2 diabetes. It was the first approval the drug received ...",
                "category": "company",
                "datetime": 1786635180,
                "headline": "Lilly gains access to market that could add millions of customers"
              },
              {
                "id": 141206477,
                "url": "https://finnhub.io/api/news?id=c672ec9f7983ec6d30d230996f287f80d4b437199519701fa447b7eaf2cccbae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the country. The approval adds a non injectable option alongside Novo Nordisk's GLP 1 based obesity drugs and could affect demand patterns if Foundayo is adopted in public healthcare settings. In the US, Amazon Pharmacy launches a new Medicare weight loss drug program priced at $50 per month that will include Novo Nordisk and Eli Lilly medications. These...",
                "category": "company",
                "datetime": 1786633954,
                "headline": "Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs"
              },
              {
                "id": 141206478,
                "url": "https://finnhub.io/api/news?id=7b9afcf9b297d62d0efe186add522f252482e96930bf7cbea6d22746df06aace",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "WOONSOCKET, RI / ACCESS Newswire / August 13, 2026 /Originally published on CVS Health Company Newsroom CVS Pharmacy offers all FDA approved GLP-1s, whether through insurance or cash-pay options. New collaboration with Eli Lilly and Company will provide ...",
                "category": "company",
                "datetime": 1786631400,
                "headline": "CVS Health Enhances Its Direct-to-Consumer Weight Management Offerings To Improve Access, Affordability, Care and Support for GLP-1 Medications"
              },
              {
                "id": 141206479,
                "url": "https://finnhub.io/api/news?id=03455f363946b459bd3bd83e124abd6cb74fad97af2be9b1af27bd9a517a575e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "NVO's GLP-1 pills offer fresh momentum, but Eli Lilly's fast-growing injectable and oral therapies threaten to widen the competitive gap.",
                "category": "company",
                "datetime": 1786631160,
                "headline": "Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?"
              },
              {
                "id": 141206480,
                "url": "https://finnhub.io/api/news?id=665a818bd51b35bfdd0d8f6581ef700c4d80e9b4b40724610d4e95c6ca122c44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.",
                "category": "company",
                "datetime": 1786629900,
                "headline": "2 S&P 500 Stocks with Exciting Potential and 1 We Ignore"
              },
              {
                "id": 141206481,
                "url": "https://finnhub.io/api/news?id=f397d1b9ffa8fea2a6d0e3e4aa497a8434b0ecb1d4424eec8bbc563314b6c2a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly's Foundayo records $98M in Q2 sales, while rising prescriptions, broader access and global expansion set the stage for H2 growth",
                "category": "company",
                "datetime": 1786628520,
                "headline": "LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?"
              },
              {
                "id": 141205460,
                "url": "https://finnhub.io/api/news?id=bdde47d7e2c81054a628fcbda4d76bd9729392f5bb1b8361b8b71aff9864d93d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upsideMIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an additional $125 million aggregate principal amount of senior secured notes. The newly issued notes are secured by OPKO’s royalty interests aris",
                "category": "company",
                "datetime": 1786626900,
                "headline": "OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests"
              },
              {
                "id": 141205461,
                "url": "https://finnhub.io/api/news?id=3e8c6b5b588b6fb76f2d072ee68087552deaa82564a5299a0a7abda6956937fd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to the right buyer. The question is which pharma giant moves first.",
                "category": "company",
                "datetime": 1786626308,
                "headline": "Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover"
              },
              {
                "id": 141204712,
                "url": "https://finnhub.io/api/news?id=f2072a0c3898ab991e3e1e7084ad6138a90f89eb2bc0a8ff6c75d4e465c2e276",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly is suing several US companies that are allegedly selling illegal versions of its weight loss candidate, retatrutide.",
                "category": "company",
                "datetime": 1786618853,
                "headline": "Eli Lilly cracks down on illicit weight loss drug trade with US lawsuits"
              },
              {
                "id": 141203838,
                "url": "https://finnhub.io/api/news?id=b33f48fc75f1b9ffcfdf982f5269f978b42b2ad1137e5f452919966d0bda6944",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2249791973/image_2249791973.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "Key Contributors include Palo Alto Networks, ASML Holding, and Taiwan Semiconductor. Read more here.",
                "category": "company",
                "datetime": 1786596000,
                "headline": "American Century Focused Global Growth Fund Q2 2026 Portfolio Review"
              },
              {
                "id": 141208941,
                "url": "https://finnhub.io/api/news?id=5708bf80b33dd6bccd825d71319ac078bb355ec1b2cfa36c01c3fb680a7feaa1",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/13/Artificial-Intelligence-Simplifying-Task.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Vinod Khosla says AI is revolutionizing drug discovery, but drug testing needs to catch up with more human-relevant methods.",
                "category": "company",
                "datetime": 1786595630,
                "headline": "Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’"
              },
              {
                "id": 141200399,
                "url": "https://finnhub.io/api/news?id=7b83f6fe1d09767db8442265a1fd0ea7bd1231cf12af9b27e917da058852a16e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Revenue surged 48% on Mounjaro and Zepbound demand, with full-year guidance raised.",
                "category": "company",
                "datetime": 1786591208,
                "headline": "Eli Lilly (LLY) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141200400,
                "url": "https://finnhub.io/api/news?id=87ba8f8cc2f71a9dc4a777a4bb155ae081cb42cdef5dfa311467672a5bcfe8e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk's CEO conceded Eli Lilly is gaining market share even as oral Wegovy hits record prescriptions and the stock keeps falling.",
                "category": "company",
                "datetime": 1786588582,
                "headline": "Novo Nordisk CEO Concedes Eli Lilly’s Market-Share Gains as Stock Slumps"
              },
              {
                "id": 141200401,
                "url": "https://finnhub.io/api/news?id=9f8326d5bf4c5cc8712afd3a3a64b28f795699272f51d641a706f97680ee3451",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The drugmaker's operating numbers are near the top of its class, but its stock performance is lagging the pack. Is the market seeing a risk that the fundamentals are missing.",
                "category": "company",
                "datetime": 1786567769,
                "headline": "How ABBV Stock Moved Away From Its Peer Group"
              },
              {
                "id": 141207573,
                "url": "https://finnhub.io/api/news?id=89ed292199e74d3978c07bd7f5a04692e7bccd0bcc24f7388c74c07ff1769591",
                "image": "https://image.cnbcfm.com/api/v1/image/108348844-4ED3-MM-B-BLOCK-SHORT-081226.jpg?v=1786576505&w=1920&h=1080",
                "source": "CNBC",
                "related": "LLY",
                "summary": "Novo Nordisk President and CEO Mike Doustdar joins 'Mad Money' host Jim Cramer to talk quarterly results, launching its GLP-q pill, competition in the weight-loss drug space, and more.",
                "category": "company",
                "datetime": 1786563973,
                "headline": "Competition has to be fierce, but competition also has to be fair, says Novo Nordisk CEO Doustdar"
              },
              {
                "id": 141200402,
                "url": "https://finnhub.io/api/news?id=77df8fb784321d9a75d391b496f979989617047f58ff619ad4660cf7bbf32319",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Wegovy pill upside has already played out, leaving the multiple at the European pharma average",
                "category": "company",
                "datetime": 1786555751,
                "headline": "Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market"
              },
              {
                "id": 141200403,
                "url": "https://finnhub.io/api/news?id=2226e5e7e6aa3331318289ceb3f548702ea39800d9ec1cb7ab4ea34f8839112d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly is trying to protect an experimental obesity medicine from unauthorized sellers before regulators decide whether to approve it.",
                "category": "company",
                "datetime": 1786555458,
                "headline": "Eli Lilly Stock Falls While Retatrutide Lawsuits Expand"
              },
              {
                "id": 141200404,
                "url": "https://finnhub.io/api/news?id=d9cd2bbfa4db96d53447581052506c53be389563f2aac9f90c4f758598be227d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development support from Eli Lilly tied to the program. See our latest analysis for Absci. Absci’s recent early Phase 1 ABS-201 update and Eli Lilly’s US$40 million commitment arrive after a sharp run, with the share price delivering a 77.55% 90 day return and a 160.66% year to date share price return, alongside a very large 3 year total shareholder...",
                "category": "company",
                "datetime": 1786554676,
                "headline": "Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation"
              },
              {
                "id": 141200405,
                "url": "https://finnhub.io/api/news?id=837baaaf97c43c97addba596e631f41eb1a913baee57218b0d21022bd85595a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "The company has referred more than 200 sellers and individuals to regulators.",
                "category": "company",
                "datetime": 1786553657,
                "headline": "Lilly Targets Black-Market Retatrutide Sellers"
              },
              {
                "id": 141200406,
                "url": "https://finnhub.io/api/news?id=620649fc4d91fc0bbdddeb8dd223c8013c7e514f492732b1bdd45dd29ca8e960",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "NVO faces near-term pressure from flat Wegovy sales, pricing challenges and pipeline setbacks, but its broad cardiometabolic pipeline offers long-term potential.",
                "category": "company",
                "datetime": 1786547400,
                "headline": "Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?"
              },
              {
                "id": 141200407,
                "url": "https://finnhub.io/api/news?id=3d4976f509abb60cfa4a755d78912638903405f4f6f5178c1b363bd7a7279a15",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "PFE's non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.",
                "category": "company",
                "datetime": 1786546980,
                "headline": "Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?"
              },
              {
                "id": 141200408,
                "url": "https://finnhub.io/api/news?id=fe056bfb43a683ba5e369be883cd1a52a455832f284ae6c1c5e25058cbde8ab9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Obesity-drug giant Eli Lilly stock is approaching a new buy point as the ongoing stock market rally strengthens.",
                "category": "company",
                "datetime": 1786544948,
                "headline": "IBD 50 Stocks To Watch: Obesity Drug Giant Eli Lilly Offers New Buy Point"
              },
              {
                "id": 141192658,
                "url": "https://finnhub.io/api/news?id=ab20d3fac01fdbbb49072572815454939c62922e0f8a3cfd272eecffef68e391",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "LLY",
                "summary": "Eli Lilly (LLY) shows a strong technical breakout setup with a 10/10 rating, tight consolidation, and defined support/resistance levels.",
                "category": "company",
                "datetime": 1786537892,
                "headline": "Eli Lilly (NYSE:LLY) Shows a Strong Technical Breakout Setup"
              },
              {
                "id": 141193636,
                "url": "https://finnhub.io/api/news?id=7bfc4b9332d97a09de7dfbe3cb43cc3e1d4b127d00f25ae64f7b45081dc0433c",
                "image": "",
                "source": "SeekingAlpha",
                "related": "LLY",
                "summary": "",
                "category": "company",
                "datetime": 1786536901,
                "headline": "I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade)"
              },
              {
                "id": 141200409,
                "url": "https://finnhub.io/api/news?id=eba78f8c8409396091cd59778178805b4e60745f5b1548385028e1e0132c3813",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Lilly said the products being sold on the black market are unverified, unapproved, and not worth the risk.",
                "category": "company",
                "datetime": 1786536320,
                "headline": "Eli Lilly Steps Up Retatrutide Crackdown With Six New Lawsuits – CMO Hyman Says Drug Sold In Black Market Is ‘Not A Medicine’"
              },
              {
                "id": 141195185,
                "url": "https://finnhub.io/api/news?id=74fc4253cb1300007f3b3a3e8fc709b87c799a119423afd9f0d478a8546069a2",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/12/Eli-Lilly.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "LLY",
                "summary": "Eli Lilly filed six lawsuits against U.S. entities for illegally selling unapproved retatrutide, warning consumers of serious health risks.",
                "category": "company",
                "datetime": 1786534442,
                "headline": "Eli Lilly Escalates Retatrutide Fight, Reports 200-Plus Illegal Sellers to Authorities"
              },
              {
                "id": 141199697,
                "url": "https://finnhub.io/api/news?id=b8f8107bde991f7a80cff65fcbd12be32036742104e7e26d544ba8eb994a039e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "SEATTLE & CAMBRIDGE, Mass., August 12, 2026--InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of a $77 million Series B financing and the dosing of the first patient in the Phase 1 clinical study of IDP-001, the company’s lead oncology program.",
                "category": "company",
                "datetime": 1786534200,
                "headline": "InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001"
              },
              {
                "id": 141200411,
                "url": "https://finnhub.io/api/news?id=49cae688322586f945775a9167cbd06c95c05e8567ac9e52f5455e76eb2aaca4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.",
                "category": "company",
                "datetime": 1786533540,
                "headline": "Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide"
              },
              {
                "id": 141200412,
                "url": "https://finnhub.io/api/news?id=991c6105345e5fd5042d249de0a63d4b3a0b06b1a9f6c8fe626021fda396019b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to having referred hundreds of bad actors to regulators and law enforcement worldwide. Lilly is also calling on the entities that sellers use to conduct their illegal business—social media and e-commerce platforms, credit card companies, payment processors and shipping and",
                "category": "company",
                "datetime": 1786527000,
                "headline": "Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market"
              },
              {
                "id": 141200413,
                "url": "https://finnhub.io/api/news?id=9a44750e56a403e0e781caac265f96a7550f3f928b741b946709f7242a385cd8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Absci Corporation recently reported second-quarter 2026 results showing a net loss of US$33.21 million, wider than a year ago, while basic and diluted loss per share from continuing operations narrowed to US$0.21. Alongside these figures, Absci highlighted encouraging early Phase 1 data for ABS-201, its prolactin receptor antibody, and a US$40 million investment and development support from Eli Lilly that extend its cash runway into the second half of 2028. Next, we’ll examine how Eli...",
                "category": "company",
                "datetime": 1786518642,
                "headline": "Absci (ABSI) Is Up 11.0% After Lilly Backs ABS-201 With US$40 Million Investment – Has The Bull Case Changed?"
              },
              {
                "id": 141200414,
                "url": "https://finnhub.io/api/news?id=15860036ec5b5cf252bdb50c6743d2404ee09214a10f28f7e960c00b86035ea9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Moby summary of Absci Corporation's Q2 2026 earnings call",
                "category": "company",
                "datetime": 1786494137,
                "headline": "Absci Corporation Q2 2026 Earnings Call Summary"
              },
              {
                "id": 141200415,
                "url": "https://finnhub.io/api/news?id=357d19f0da6cf1bc204840b235e6b08965ba186d9a51a09711e280f46a2aa98e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "LLY",
                "summary": "Novo Nordisk is playing catch-up in the GLP-1 race.",
                "category": "company",
                "datetime": 1786494000,
                "headline": "Better Buy: Eli Lilly vs. Novo Nordisk"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 242,
            "discarded_article_count": 221
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 11.5,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 0.6,
          "macdPoints": 0.8,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.6,
            "vcp_reason": "跌縮量(近10日5日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 2739143.3333333335,
              "down_days": 6,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 2441290,
              "avg_vol_20": 2469875,
              "avg_vol_30": 2739143.3333333335,
              "range_pct_10": 0.06862054623198637,
              "range_pct_20": 0.1605270036984406,
              "range_pct_30": 0.1644707432316368,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8912604062340659,
              "dist_to_20d_high": 0.13688938789479932,
              "down_shrink_days": 5,
              "breakout_level_20d": 1292.65002,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.41722038147138896
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 0.8,
          "volumeWeight": 2,
          "maCrossPoints": 0.8,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.4896478663461443,
              "turnoverUsdM": 2047.4321352445,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.LLY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 1060.1459,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 2,
              "rsi_score": 2.5,
              "macd_score": 1,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 5,
            "take_profit_price": 1171.4849,
            "target_multiplier": 1.6,
            "technical_strength": 1.45,
            "take_profit_percent": 5
          },
          "positionPoints": 1.8,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.979295732692289,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.LLY",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 71.43,
    "atr": {
      "atr": 27.777,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.49
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -110.64
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.192
    },
    "kdj": {
      "d": 12.72,
      "j": 2.9,
      "k": 9.45,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 21.01
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 3175390,
      "recentSlope": -704621,
      "previousSlope": -325380
    },
    "rsi": 2.48,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 1191.5461,
      "position": "SAR喺價上",
      "distancePct": 6.8,
      "previousTrend": "下降"
    },
    "ma50": 1184.6546,
    "macd": {
      "macd": -18.821867610831987,
      "trend": "看跌",
      "signal": -9.001190716720334,
      "histogram": -9.820676894111653
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 1189.5738,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.74,
      "score": 2,
      "avgVolume": 2465266,
      "currentVolume": 1835110
    },
    "derived": {
      "ma20": 1183.1245,
      "ma50": 1184.6546,
      "prevClose": 1123,
      "avgVolume10": 2351741,
      "avgVolume20": 2465266,
      "changePercent": -0.65,
      "avgVolumeForScore": 2465266
    },
    "ma_cross": {
      "ma20": 1183.1245,
      "ma50": 1184.6546,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "下穿",
      "score": 2,
      "prevMa20": 1187.7895,
      "prevMa50": 1186.1754,
      "spreadPct": 0.13,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 1087.5904,
      "upper": 1278.6586,
      "position": "中間"
    },
    "rsi_short": 0.67,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.74
    }
  }
}

{
  "close": 1115.7,
  "volume": 1835110,
  "changePercent": -0.65
}